Vaccine composition

By covalently linking the CRM197 carrier protein with an immunogenic peptide, the problems of poor immune response and poor reproducibility of existing MUC1 vaccines have been solved, achieving potent cancer vaccine activation and homogeneous production, and delaying tumor growth.

CN121666244APending Publication Date: 2026-03-13FUNDAÇÃO GIMM- GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202480052155.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-14
Filing Date
2024-06-11
Publication Date
2026-03-13

AI Technical Summary

Technical Problem

Existing MUC1 vaccines exhibit poor immune responses in tumor cells, and their heterogeneous conjugates lead to poor reproducibility and strong immune tolerance, making it impossible to effectively elicit a potent immune response against MUC1.

Method used

A cancer vaccine conjugate was developed by covalently linking the C186 and C201 residues of the CRM197 carrier protein with an immunogenic peptide to form a homogeneous cancer vaccine conjugate containing a linker ZLD, where Z is the CRM197 carrier protein, L is the linker, and D is the immunogenic peptide. The conjugate is covalently linked using an azide group and a cyclooctyne group to activate the Th1 immune response.

Benefits of technology

It achieves homogeneous vaccine production, stimulates a strong immune response against cancer cells expressing MUC1, reduces enzymatic degradation and tolerance, promotes cytotoxic T lymphocyte response, delays tumor growth and prolongs survival.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to vaccines, particularly conjugated vaccines and methods for their production. Background Technology

[0002] Mucin-1 (MUC1) is highly expressed on the surface of epithelial cells. O - Glycosylated glycoprotein. Its extracellular domain contains a tandem repeat of 20 amino acids (AHGVTSAPDTRPAPGSTAPP), which contains five potential amino acids. O - Glycosylation sites (as indicated by bold letters in the peptide sequence) (1, 2). Although the protein carries complex oligosaccharides in healthy tissues, MUC1 is modified with simple and truncated glycosides in tumor cells, where MUC1 expression is significantly increased due to dysfunction or translocation of GalNAc transferase (2) or mutations in COSMC (the molecular chaperone required for the activity of glycosyltransferase C1GalT) (6) (3-5). As a result, the immunogenic epitope APDTRP (7, 8) and several tumor-associated carbohydrate antigens (TACAs) (e.g., Tn antigens (α-O-GalNAc-Ser / Thr, hereinafter referred to as Tn-Ser and Tn-Thr, respectively) are exposed and may elicit a weak immune response (9). (9) The development of MUC1-based vaccines has been influenced by the discovery that cancer patients may produce anti-MUC1 antibodies in the early stages of the disease (10, 11). These vaccines typically contain the full-length MUC1 glycosylated sequence at one or more sites, where Tn or other TACAs are conjugated to protein carriers, liposomes, or nanoparticles (12-18). This strategy facilitates multiplex presentation of antigens, but on the other hand, it leads to heterogeneous conjugates that may result in poorly reproducible formulations. Despite these synthetic efforts, there have been no successful clinical applications (19), likely because aberrantly glycosylated proteins are present even in low concentrations on healthy cells (PMID: 34526666), leading to immune system tolerance and consequently poor immune responses in preclinical mouse models. Summary of the Invention

[0003] The inventors of this application have developed a cancer vaccine conjugate that produces a potent immune response against tumors and can be produced in a highly reproducible manner in a homogeneous form.

[0004] A first aspect of the present invention provides a cancer vaccine conjugate comprising: CRM 197 Carrier proteins, Immunogenic peptides, and Linker that connects the immunogenic peptide to the CRM 197 The residues C186 and C201 of the vector are covalently linked. And its salts, solvates and protected forms.

[0005] Suitable, the cancer vaccine conjugate may have the formula: ZLD in: Z is CRM 197 Carrier proteins, L is a connector, and D is an immunogenic peptide.

[0006] In some preferred embodiments, the cancer vaccine conjugate of the first aspect can stimulate an immune response against cancer cells expressing mucin-1 (MUC1). For example, the immunogenic peptide can be a natural or synthetic MUC1 glycopeptide.

[0007] A second aspect of the invention provides a method for producing cancer vaccine conjugates. CRM provided with covalent connection to the first connector 197 Carrier proteins, The first connector is connected to the CRM 197 The carrier protein has residues C186 and C201 covalently linked and contains a first reactive group. Provides an immunogenic peptide covalently linked to a second linker. The second linker contains a second reactive group. The first and second reactive groups react to covalently link the first and second linkers, thereby linking the immunogenic peptide to the CRM. 197 The cancer vaccine conjugate is generated on the carrier protein.

[0008] In some preferred embodiments, the first reactive group may be an azide group, and the second reactive group may be a cyclooctyne group.

[0009] CRM 197 The carrier protein can be covalently linked to the first linker by the following methods, for use in the second aspect of the method, which includes: Provide CRM 197 Carrier proteins, Selectively restore the CRM 197 The C186-C201 disulfide bond of the carrier protein, in the CRM 197 Free thiol groups are generated at residues C186 and C201 of the carrier protein. Provided is a first linker compound comprising a first reactive group, a third reactive group, and a fourth reactive group, and The third and fourth reactive groups of the first linker compound react with the free thiol groups at C186 and C201, respectively, to allow the first linker to react with the CRM. 197 The carrier protein residues C186 and C201 are covalently linked, thereby enabling the CRM to... 197 The carrier protein is covalently linked to the first linker.

[0010] In some preferred embodiments, the third and fourth reactive groups may be halide groups, such as chloride groups.

[0011] The immunogenic peptides of the first and second aspects may contain tumor-specific antigens or tumor-associated antigens (TAAs), preferably tumor-associated carbohydrate antigens (TACA).

[0012] A third aspect of the present invention provides a kit for generating cancer vaccine conjugates, comprising: CRM 197 A carrier protein, covalently linked to a first linker, wherein the first linker is connected to CRM 197 The carrier protein has residues C186 and C201 covalently linked and contains a first reactive group.

[0013] The kit can be used with the method of the second aspect.

[0014] A fourth aspect of the invention provides a pharmaceutical composition comprising the cancer vaccine conjugate of the first aspect and a pharmaceutically acceptable excipient.

[0015] The fifth aspect of the invention provides a treatment method for cancer, comprising administering to an individual in need either the cancer vaccine conjugate of the first aspect or the pharmaceutical composition of the fourth aspect.

[0016] The sixth aspect of the present invention provides a cancer vaccine conjugate of the first aspect or a pharmaceutical composition of the fourth aspect for treating cancer.

[0017] The seventh aspect of the invention provides the use of the cancer vaccine conjugate of the first aspect or the pharmaceutical composition of the fourth aspect in the manufacture of a medicament for treating cancer.

[0018] Other aspects and embodiments of the invention will be described in more detail below. Attached Figure Description

[0019] Figure 1 illustrates the method of the present invention for preparing a cancer vaccine based on a non-natural MUC1-derived glycopeptide. (a) Schematic diagram of the cancer vaccine conjugate. (b) Structure of the MUC-1-derived glycopeptide. (c) Structure of the N-terminal portion R (1').

[0020] Figure 2(a) This work shows the selective modification of CRM. 197 Optimized conditions for cysteine ​​residues 186 and 201 in the protein. (b) CRM 197 - ESI-MS spectra of linker-azides. (c) CRM 197 and CRM 197 -Linker-Azide CD spectrum

[0021] Figure 3 (a) is shown in this work, representing the CRM used to prepare the vaccine candidate. 197 - Optimization conditions for connector-1'. (b) CRM 197 - ESI-MS spectrum of linker-1'. (c) Representative conformational ensemble obtained from MD simulations. The protein is shown as a white ribbon, and the carbon atoms of the linker, MUC1, and GalNAc are represented as blue, green, and orange sticks, respectively. These calculations take into account... E -Oxime and 1,5-triazole adduct.

[0022] Figure 4 (a) The vaccine administration protocol used in this work is shown. (b) CRM at different stages is shown. 197 -Connector-1', CRM 197 (d) Total levels of IgG antibodies induced by PBS, as determined by ELISA analysis. (d) IgG isotypes detected after the fourth immunization, as determined by ELISA analysis. (d) IgG isotypes detected by CRM after the fourth immunization. 197 -Connector-1', CRM 197 Total levels of PBS-induced IgM antibodies, as determined by ELISA analysis. Flow cytometry analysis investigated binding with (e) HEK293T cells (negative control) and (f) TD47 cells expressing TA-MUC1 on their surface. Black line: serum from mice injected with PBS; Blue line: commercial anti-MUC1 antibody; Pink line: serum from mice injected with CRM. 197 Serum from immunized mice; red line: from CRM 197 Serum from mice immunized with -MUC1. (e) Statistical significance was determined by unpaired t-test.

[0023] Figure 5The following data are presented: (a) Tumor weight measured on day 15 after tumor induction (MC38-MUC1 cells). Mice were treated with different formulations before tumor induction. No statistically significant differences were observed. (b) Tumor volume measured after tumor induction with different formulations. (c) Circulating Th1 cytokine levels in mice treated with different conjugates after tumor induction. (d) Circulating Th2 cytokine levels in mice treated with different conjugates after tumor induction. No statistically significant differences were observed. (e) Cytotoxic T lymphocyte assay. T cells isolated from the spleen of immunized mice were co-cultured with MC38-MUC1 cells at a ratio of 90:1 (T cells:MC38-MUC1 cells) for 24 h. Decreased MC38-MUC1 cell viability was observed. Statistical significance was determined by unpaired t-test. Data represent mean + SEM. (f) Probability of survival in mice after tumor induction (MC38-MUC1 cells) and treatment with the corresponding conjugates.

[0024] Figure 6 The results showed that when CRM was therapeutically administered to a mouse model of pancreatic cancer, 197 -Linker-1' delays tumor growth and prolongs survival. Tumor volume measured after tumor induction with different formulations ( p = 0.0197) (left figure), and the survival probability of mice after tumor induction and treatment with the corresponding preparation ( p = 0.1092) (Right figure).

[0025] Figure 7 The results showed that when CRM was administered therapeutically in a combination therapy regimen of checkpoint inhibitors, 197 -Linker-1' delays tumor growth and prolongs survival. Tumor volume measured after tumor induction with different agents (MC38-MUC1 cell line (top figure)). p = 0.0362), or the Panc02-MUC1 cell line (see figure below). p = 0.0201), and the probability of mouse survival under these conditions (MC38-MUC1 cell line (top right, p = 0.1017), or the Panc02-MUC1 cell line (lower right, p =0.0163).

[0026] Figure 8 CRM was displayed 197Endotoxin levels of linker-1'. Endotoxin levels were determined in conjugate samples prior to animal administration. Two independent samples showed levels below 1 EU / mL (0.844100013 and 0.946199968). Administration to mice was considered safe if endotoxin levels were below 1.5 EU / mL.

[0027] Figure 9 Maximum tolerated dose (MTD) evaluation is shown. CRM was evaluated by administering a total of four subcutaneous (SC) injections at 2-day intervals to normal Balb / c mice after injecting different doses of the vaccine. 197 - MTD of linker-1'. Toxicity signs were examined at both the macroscopic level (e.g., weight loss and signs of pain / discomfort in mice) and the microscopic level (through histological analysis of different organs). No significant weight loss was observed, nor were any abnormalities observed in mouse tissues, indicating no signs of toxicity at the test dose of the vaccine. Detailed Implementation

[0028] This invention relates to CRM. 197 A cancer vaccine comprising a carrier protein and an immunogenic peptide, wherein the immunogenic peptide is linked to a CRM via a linker. 197 The vector residues C186 and C201 are covalently linked.

[0029] The population of cancer vaccine conjugates described herein can be homogeneous, meaning that all molecular species within the population can have the same chemically defined structure. Preferably, in the cancer vaccine conjugates described herein, a single immunogenic peptide is associated with each CRM. 197 Carrier protein covalently linked, i.e., CRM in cancer vaccine conjugates 197 The stoichiometric ratio of carrier protein to immunogenic peptide can be 1:1. The generation of cancer vaccine conjugates, as described herein, can be used to reduce batch-to-batch variability in vaccine production.

[0030] Cancer vaccine conjugates can induce antibodies that selectively recognize naturally occurring antigens corresponding to immunogenic peptides in a patient's sample. Furthermore, cancer vaccine conjugates can activate Th1 immune responses and generate T cells that promote cytotoxic T lymphocyte (CTL) responses. Cancer vaccine conjugates can exert anti-tumor effects in patients.

[0031] Compared to vaccines using natural antigens, cancer vaccine conjugates can also exhibit reduced enzymatic degradation and reduced in vivo tolerance.

[0032] The cancer vaccine conjugates described in this article contain immunogenic peptides.

[0033] Immunogenic peptides can trigger an immune response against cancer cells in an individual. For example, immunogenic peptides may contain one or more epitopes derived from tumor antigens expressed by cancer cells in an individual. Tumor antigens are well known in the art and may include protein antigens and tumor-associated carbohydrate antigens (TACAs), such as Survivin, p53, PSA, MUC-1, MUC-4, MUC-16, and CEA. Suitable epitopes may include peptide and carbohydrate epitopes.

[0034] Preferably, the immunogenic peptide can be a glycopeptide. Suitable glycopeptides can include natural or artificial glycopeptides. For example, suitable glycopeptides can include glycopeptides containing one or more glycosylation sites, such as O-, S-, Se-, or N-glycosylation sites. The glycosylation site can include serine residues, threonine residues, or non-natural amino acid residues with side chains, said side chains including hydroxyl (R-OH) groups, thiol (R-SH) or disulfide (SS) groups, or selenool (R-SeH) or diselenool (Se-Se) groups.

[0035] In some preferred embodiments, the immunogenic peptide may be a mucin 1 (MUC-1) glycopeptide.

[0036] The MUC-1 glycopeptide can be a natural mucin 1 (MUC-1) glycopeptide, or more preferably a synthetic artificial mucin 1 (MUC-1) glycopeptide. The synthetic artificial mucin 1 (MUC-1) glycopeptide may contain one or more non-natural or atypical amino acid residues, i.e., amino acid residues not encoded by the genetic code of a naturally occurring organism. Non-natural amino acid residues may include thiothreonine (SThr) and 4-fluoro-L-proline.

[0037] Synthetic artificial MUC-1 glycopeptides may further include carbohydrate antigens, such as GalNAc (Tn antigen), Galb(1,3)GalNAc (T antigen), or Neu5Acα(2-6)GalNAc (sTn antigen), or non-natural carbohydrate antigens derived from one of these antigens. The carbohydrate antigen can be linked to a glycosylation site within the peptide sequence of the glycopeptide via a glycosidic bond. For example, carbohydrate antigens (e.g., Tn, T, or sTn) can be linked to the peptide sequence via an O-glycosidic bond at a non-natural amino acid containing Ser, Thr, or R-OH. Carbohydrate antigens can be linked to the peptide sequence via an S-glycosidic bond at a non-natural amino acid containing R-SH. For example, immunogenic glycopeptides may include S-(α-D-GalNAc)-thiothreonine (SThr) or a derivative thereof. Carbohydrate antigens can be linked to the peptide sequence via a Se-glycosidic bond at a non-natural amino acid containing R-SeH.

[0038] In some preferred embodiments, the immunogenic glycopeptide may be a MUC-1 glycopeptide and may include S-(α-D-GalNAc)-thiothreonine (SThr) or a derivative thereof. Suitable MUC-1 glycopeptides may contain the amino acid sequence AX1DX2RP or a variant thereof, wherein X1 is 4. S -4-Fluoro-L-proline, and X2 is S -(α-D-GalNAc)-Thiothreonine (SEQ ID NO: 1). In some preferred embodiments, the MUC-1 glycopeptide may comprise the amino acid sequence HGVTSAX1DX2RPAPGSTAPPA or a variant thereof, wherein X1 is 4. S -4-Fluoro-L-proline, and X2 is S -(α-D-GalNAc)-thiothreonine (SEQ ID NO: 2).

[0039] In some embodiments, the immunogenic glycopeptide may contain two or more glycosylation sites. The carbohydrate antigen may be linked to the glycopeptide at two or more glycosylation sites. The carbohydrate antigens linked to the two or more glycosylation sites may be the same or different. For example, one of GalNAc (Tn antigen), Galb(1,3)GalNAc (T antigen), or Neu5Acα(2-6)GalNAc (sTn antigen) may be linked to the glycopeptide at both the first and second glycosylation sites, or one of GalNAc (Tn antigen), Galb(1,3)GalNAc (T antigen), or Neu5Acα(2-6)GalNAc (sTn antigen) may be linked to the glycopeptide at the first glycosylation site, while another of GalNAc (Tn antigen), Galb(1,3)GalNAc (T antigen), or Neu5Acα(2-6)GalNAc (sTn antigen) may be linked to the glycopeptide at the second glycosylation site.

[0040] Cross-reactive substance 197 (CRM) 197 CRM197 is a diphtheria toxin (DT) that is detoxified by the presence of a Gly-to-Glu mutation at position 52 of the wild-type CRM197 sequence corresponding to SEQ ID NO: 3 (Broker et al. (2011) Biologicals 39(4) 195-204). 197 As carrier proteins for polysaccharides and haptens, they are widely used and have been successfully used in vaccines against Haemophilus influenzae, pneumococcus, and meningococcus (e.g., Menveolar). ®(25-27) A quadrivalent conjugate vaccine against Neisseria meningitidis serogroup AC-W135-Y.

[0041] CRM 197 The carrier protein may contain the amino acid sequence of SEQ ID NO: 3 or a variant thereof.

[0042] Variants of the reference sequence described herein (e.g., reference immunogenic glycopeptide or CRM) 197 A variant of the sequence may contain an amino acid sequence that has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% sequence identity with the reference sequence. A particular amino acid sequence variant may differ from the reference sequence shown herein by inserting, adding, substituting, or deleting one, two, three, four, five, six, seven, eight, nine, or ten or more amino acids.

[0043] Sequence similarity and identity are typically defined using the GAP algorithm (Wisconsin Package, Accelerys, San Diego, USA). GAP uses the Needleman and Wunsch algorithms to align two complete sequences, maximizing the number of matches and minimizing the number of gaps. Default parameters are usually used, with a gap creation penalty of 12 and a gap extension penalty of 4. GAP is preferred, but other algorithms, such as BLAST (which uses Altsch), can also be used. et al. (1990) J. Mol. Biol 215: 405-410, FASTA (which uses Pearson and Lipman (1988)). PNAS USA 85: Methods 2444-2448) or the Smith-Watman algorithm (Smith and Waterman (1981)). J. Mol Biol. 147 Methods 195-197, or the TBLASTN program (Altschul et al. (1990), ibid.), are typically used with default parameters. In particular, the psi-Blast algorithm (Nucl. Acids Res. (1997) 25 3389-3402) can be used.

[0044] CRM 197 It can be generated through the reorganization of established technologies or obtained from commercial suppliers.

[0045] In the vaccine conjugates described herein, immunogenic glycopeptides are covalently linked to CRM. 197 The carrier protein residues C186 and C201 are linked.

[0046] Connector in CRM 197 A bridge is formed between carrier protein residues C186 and C201, connecting the immunogenic glycoprotein to CRM. 197 Carrier protein linker. The linker can be covalently linked to (i) CRM. 197 Residues C186 and (ii) CRM of the vector 197 The carrier residues C201 and (iii) the N-terminus of the MUC-1 glycopeptide.

[0047] Connector-L- is used to enable CRM 197 The carrier Z- is linked to a group of immunogenic glycopeptide-D.

[0048] It should be understood that any suitable connector can be used to enable CRM. 197 The carrier protein is linked to the immunogenic glycopeptide.

[0049] In some embodiments, the linker may comprise one or more groups selected from polyethylene glycol moieties, amino acid residues, alkylene diamine moieties, arylene moieties, heteroarylene moieties, heterocyclic moieties, cycloalkyl moieties, and combinations thereof.

[0050] Suitablely, the linker comprises 1 to 20 of the aforementioned groups. More suitablely, the linker comprises 1 to 15 of the aforementioned groups. Even more suitablely, the linker comprises 1 to 10 of the aforementioned groups.

[0051] Suitable, the linker comprises one or more groups selected from polyethylene glycol moieties, amino acid residues, alkylene diamine moieties, and combinations thereof.

[0052] The polyethylene glycol portion will be understood as a functional group comprising one or more alkylene glycol portions (e.g., one or more ethylene glycol portions). In some embodiments, the linker comprises 1 to 20 alkylene glycol portions (e.g., ethylene glycol portions), preferably 1 to 10 alkylene glycol portions (e.g., ethylene glycol portions), and most preferably 2 to 8 alkylene glycol portions (e.g., ethylene glycol portions).

[0053] The alkylene diamine moiety will be understood as a functional group that includes or is derived from an alkylene diamine moiety (e.g., ethylenediamine).

[0054] The arylene moiety will be understood as a functional group containing one or more arylene groups. Suitable, the arylene will be a 6-membered arylene, such as a phenylene group. In some embodiments, the arylene moiety is a functional group containing a 1,3,5-benzyl group.

[0055] The heteroarylene moiety will be understood as a functional group containing one or more heteroarylene groups. Suitablely, the heteroarylene will be a functional group containing a six-membered heteroarylene (e.g., a triazine). In some embodiments, the heteroarylene moiety is a functional group containing a 1,3,5-triazine group.

[0056] The heterocyclic moiety will be understood as a functional group containing one or more heterocyclic groups. Suitablely, the heterocycle is a six-membered heterocycle, such as a triazine. In some embodiments, the heterocyclic moiety is a functional group containing a 1,3,5-triazine alkyl group.

[0057] The cycloalkyl moiety will be understood as a functional group containing one or more cycloalkyl groups. Suitablely, the cycloalkyl group is a six-membered cycloalkyl group, such as cyclohexane. In some embodiments, the cycloalkyl moiety is a functional group containing 1,3,5-cyclohexane.

[0058] Amino acid residues will be understood as both natural and non-natural amino acid residues. Appropriately, amino acid residues will be natural amino acid residues. Amino acid residues may also contain two or more amino acids, such as, for example, dipeptide and tripeptide motifs. Suitable amino acid residues include Phe, Lys, Val, Ala, Cit, Leu, Ile, Arg, and Trp residues.

[0059] In some embodiments, the amino acid residues are dipeptide residues. The amino acids in the dipeptide can be any combination of natural and non-natural amino acids. In some embodiments, the dipeptide contains natural amino acids.

[0060] In some implementations, the linker is a cathepsin-unstable linker, and the dipeptide is the site of action for cathepsin-mediated cleavage. Therefore, the dipeptide is the recognition site for cathepsins.

[0061] In some implementations, the amino acid residues are selected from: NH -Phe-Lys- C=O , NH Val-Ala- C=O , NH Val-Lys- C=O , NH Ala-Lys- C=O , NH -Val-Cit- C=O , NH -Phe-Cit- C=O , NH -Leu-Cit- C=O , NH -Ile-Cit- C=O , NH -Phe-Arg- C=O ,and NH -Trp-Cit- C=O ; Wherein Cit is citrulline, and NH and C=O are the amino and carboxyl ends of the amino acid residues, which are then linked to the remainder of the linker.

[0062] Preferably, the amino acid residues are selected from: NH -Phe-Lys- C=O , NH -Val-Ala- C=O , NH -Val-Lys- C=O , NH -Ala-Lys- C=O ,and NH -Val-Cit- C=O .

[0063] Most preferably, the amino acid residues are selected from... NH -Phe-Lys- C=O , NH -Val-Cit- C=O or NH -Val-Ala- C=O .

[0064] Other dipeptide combinations can be used, including those made from Dubowchik. et al ., Bioconjugate Chemistry The combinations described in , 2002, 13, 855-869 are incorporated herein by reference.

[0065] In some embodiments, the amino acid residues are tripeptide residues. The amino acids in the tripeptide can be any combination of natural and non-natural amino acids. In some embodiments, the tripeptide contains natural amino acids.

[0066] When the linker is an unstable linker for cathepsins, the tripeptide is the site of action for cathepsin-mediated cleavage. Therefore, the tripeptide is the recognition site for cathepsins.

[0067] Mentioning amino acids and amino acid residues usually refers to α-amino acids.

[0068] Under appropriate conditions, amino acid side chains can be chemically protected. The protected amino acid sequence may then be enzymatically cleaved. For example, a dipeptide sequence containing a Lys residue protected by a Boc side chain can be cleaved by cathepsins.

[0069] Protecting groups for amino acid side chains are well known in the art and are described in the Novabiochem product catalog.

[0070] In some embodiments, the linker-L- comprises one or more groups susceptible to enzymatic cleavage (e.g., proteolytic or peptidase cleavage, such as cathepsin cleavage, sulfatase cleavage, or galactosidase cleavage). Therefore, in some embodiments, the linker-L- comprises one or more amino acid residues, dipeptide residues, or tripeptide residues, one or more aryl sulfates, one or more aryl galactosides, or combinations thereof. Suitably, the linker-L- comprises one or more amino acid residues, dipeptide residues, or tripeptide residues, wherein the amino acid residues, dipeptide residues, or tripeptide residues are as described below.

[0071] In some embodiments, the linker -L- is or contains one or more groups (e.g., disulfide or hydrazone) that are susceptible to chemical cleavage.

[0072] In other embodiments, the linker may be a non-cleavable linker. Such non-cleavable linkers are well known in the field of antibody-drug conjugates.

[0073] Therefore, in some implementations, the connector -L- is or contains a selection from C1-C 20 One or more groups including alkylene groups, (poly)ethylene glycol moieties, alkylene diamine moieties, amino acid residues, and combinations thereof.

[0074] In some embodiments, the linker is a group of formula V, as shown below:

[0075] Formula V

[0076] in: Z A It is a protein linker group; Q is a spacer group; Instruction connector and CRM 197 The location where the carrier protein is linked; and Indicates the location where the linker connects to the immunogenic glycopeptide.

[0077] Protein linker ZA It can enable CRM 197 Any functional group that links a carrier protein to a linker. Therefore, the protein linker group Z... A It can be integrated with CRM 197 The sulfur atoms present on the carrier protein form covalently linked functional groups. Appropriately, the sulfur atoms are derived from CRM. 197 The sulfur atoms at residues C186 and C201 of the carrier protein. Therefore, it should be understood that this linker is used to rebridge CRM. 197 Reduced interchain disulfide bonds between residues C186 and C201 of the carrier protein.

[0078] This way, CRM can be made 197 Functional groups for linking carrier proteins to linkers are well known in the art. Therefore, those skilled in the art will be able to select suitable protein linker groups for use in this invention. Suitable protein linker groups Z A Examples include those described in the following literature, such as Xu 2021 (ChemRxiv. Cambridge:Cambridge Open Engage; 2021, 1-17), Stieger 2021 (Angew. Chemie Int. Ed.,2021, 60, 1-7), Walsh 2019 (Chem. Sci., 2019, 10, 694–700), Walsh 2020 (Org.Biomol. Chem., 2020, 18, 4224–4230), Badescu 2014 (Bioconjug. Chem., 2014, 25,1124–1136), Koniev 2018 (Medchem comm, 2018, 9, 827–830), Robinson 2017 (RSCAdv., 2017, 7, 9073–9077), Behrens 2015 (Mol. Pharm., 2015, 12, 3986–3998) and WO2019 / 011078.

[0079] In some implementations, Z A Selected from one of the following protein linker groups: , , , ,

[0080] in: Instruction Z A With CRM 197 The location where the carrier protein is linked; and Instruction Z A The position where it is attached to the spacer group Q.

[0081] In some implementations, Z A These are the following protein linker groups:

[0082] in: Instruction Z A With CRM 197 The location where the carrier protein is linked; and Instruction Z A The position where it is attached to the spacer group Q.

[0083] In some embodiments, Q is a spacer comprising one or more groups selected from polyethylene glycol moieties, amino acid residues, alkylene diamine moieties, arylene moieties, heteroarylene moieties, heterocyclic moieties, cycloalkyl moieties, and combinations thereof.

[0084] Each of the polyethylene glycol moiety, amino acid residue, alkylene diamine moiety, arylene moiety, heteroarylene moiety, heterocyclic moiety, and cycloalkyl moiety is preferably any of the groups defined above.

[0085] In some preferred embodiments, Q is a spacer containing components selected from C1-C2. 20 One or more groups including alkylene groups, polyethylene glycol moieties, amino acid residues, alkylene diamine moieties, and combinations thereof.

[0086] As described below, a connector can be formed by covalently linking a first connector and a second connector. The first connector can be connected to the CRM. 197 The carrier protein is covalently linked, and the second linker can be covalently linked to an immunogenic glycopeptide. A covalent link is formed between the first and second linkers, thereby forming a linker-L-, which covalently links to the CRM. 197 Carrier proteins and immunogenic glycopeptides.

[0087] Therefore, in some embodiments, the spacer group Q is a group of formula VI, as shown below: -Q1-FG-Q2- Style VI in: Q1 is related to CRM.197 The first spacer group covalently linked to the carrier protein; Q2 is a second spacer group covalently linked to the immunogenic glycopeptide; and FG is a functional group that connects Q1 and Q2.

[0088] It should be understood that the first spacer group Q1 and the second spacer group Q2 can be any of the groups associated with the spacer group Q or the linker L as defined herein.

[0089] In some preferred embodiments, the first spacer group Q1 and the second spacer group Q2 independently comprise components selected from C1-C1. 20 One or more groups including alkylene groups, (poly)ethylene glycol moieties, alkyldiamine moieties, amino acid residues, and combinations thereof.

[0090] In some preferred embodiments, the first spacer group Q1 is a group of the following formula:

[0091] in: n is an integer from 1 to 6, preferably from 1 to 4, and most preferably 2; Indicates the first spacer group Q1 and the protein linker group Z A The location of the connection; and Indicates the position where the first spacer group Q1 is connected to the functional group FG.

[0092] In some preferred embodiments, the second spacer group Q2 is a group of the following formula:

[0093] in: m is an integer from 1 to 8, preferably from 2 to 6, and most preferably 4; Indicates the position where the second spacer group -Q2- is attached to the functional group FG; and Indicates the position where the second spacer group -Q2- is linked to the immunogenic glycopeptide D.

[0094] In some embodiments, FG is a bond or functional group formed by the reaction between: i) a ketone or aldehyde and an alkoxyamine (e.g., hydroxylamine) or hydrazine; ii) an azide and an alkyne; iii) an amine and an acyl halide or carboxylic acid; iv) an electron-rich dienophile (e.g., a 1,3-nitroketone alkene) and an electron-deficient diene (e.g., a tetrazine); and iii) a strained alkene or alkyne (e.g., norbornene or cyclooctyne) and a tetrazine. Suitably, FG is a bond or functional group formed by the reaction of an azide with an alkyne, or an amine with an acyl halide or carboxylic acid. Most suitably, FG is a functional group formed by the reaction between an azide and an alkyne.

[0095] Therefore, in some implementations, FG is selected from key, , , , , Functional groups of -NH(=O)C- and -C(=O)NH-.

[0096] In some implementations, FG is selected from , , , and .

[0097] Preferably, FG is selected from or .

[0098] In some preferred embodiments, the linker is a group of the following formula:

[0099] in; n is an integer selected from 1 to 4 (preferably 2); m is an integer selected from 2 to 8 (preferably 4); It's CRM 197 Residues C186 and C201 of the carrier protein, linker and CRM 197 The carrier protein is linked at the two residues mentioned above; and Indicates the location where the linker connects to the immunogenic glycopeptide (e.g., the N-terminus of the MUC-1 glycopeptide).

[0100] The methods for generating cancer vaccine conjugates as described herein may include: CRM provided with covalent connection to the first connector 197 Carrier proteins, The first connector is connected to the CRM 197 The carrier protein has residues C186 and C201 covalently linked and contains a first reactive group. Provides an immunogenic glycopeptide covalently linked to a second linker. The second linker comprises a second reactive group, and The first and second reactive groups are reacted to allow the immunogenic glycopeptide to react with the CRM. 197 The carrier protein is covalently linked to generate the cancer vaccine conjugate.

[0101] The first and second reactive groups can react together to allow the immunogenic glycopeptide to react with CRM. 197 Any functional group covalently linked to the carrier protein.

[0102] In some implementations, the first reactive group and the second reactive group can form a covalent bond through a click chemical reaction.

[0103] In some embodiments, the first reactive group and the second reactive group are selected from the following pairs: i) Azides and alkynes; ii) Ketones or aldehydes and alkoxyamines (e.g., hydroxylamine) or hydrazine; iii) Amines and acyl halides or carboxylic acids; iv) Electron-rich dienes (e.g., 1,3-nitroketenes) and electron-deficient dienes (e.g., tetrazines); and v) Strained alkenes or alkynes (e.g., norbornene or cyclooctyne) and tetrazines.

[0104] In the above pairing, the first reactive group will be from one of the paired functional groups, while the second reactive group will be from the other (or paired) functional groups.

[0105] In some preferred embodiments, one of the first reactive group and the second reactive group is an azide, and the other of the first reactive group and the second reactive group is an alkyne.

[0106] Preferably, the first reactive group is an azide (azide group), and the second reactive group is an alkyne (alkynyl group). Most preferably, the first reactive group is an azide, and the second reactive group is a cyclooctyne, such as dibenzocyclooctyne.

[0107] Therefore, in some embodiments, the first linker is a group of formula VI, as shown below:

[0108] Style VI

[0109] in: Q1 is related to CRM. 197 The first spacer group covalently linked to the carrier protein; RG1 is the first reactive group (e.g., azide); and It's CRM 197 Residues C186 and C201 of the carrier protein, linker and CRM 197 The carrier protein is linked at the two residues mentioned above.

[0110] In some embodiments, the second linker is a group of formula VII, as shown below:

[0111] Equation VII

[0112] in: Q2 is a second spacer group covalently linked to the immunogenic glycopeptide; and RG2 is the second reactive group (e.g., an alkyne); and Indicates the location where the linker connects to an immunogenic glycopeptide (e.g., MUC-1 glycopeptide).

[0113] It should be understood that the first spacer group Q1 of the first linker and the second spacer group Q2 of the second linker can be any of the groups associated with Q1 and Q2 as defined above.

[0114] In some preferred embodiments, with CRM 197 The first linker for covalently linking carrier proteins is a group of the following formula:

[0115] in: n is an integer from 1 to 4, preferably 2; and It's CRM 197 Residues C186 and C201 of the carrier protein, linker and CRM 197 The carrier protein is linked at the two residues mentioned above.

[0116] In other preferred embodiments, the second linker covalently linked to the immunogenic glycopeptide is a group of the following formula:

[0117] in: m is an integer from 2 to 8, preferably 4; and Indicates the location where the linker connects to an immunogenic glycopeptide (e.g., MUC-1 glycopeptide).

[0118] CRM 197 The carrier protein can be covalently linked to the first linker by the following method, the method comprising: Provide CRM 197 Carrier proteins, Selectively restore the CRM 197 The C186-C201 disulfide bond of the carrier protein, in the CRM 197 Free thiol groups are generated at residues C186 and C201 of the carrier protein. Provided is a first linker compound comprising a first reactive group, a third reactive group, and a fourth reactive group, and The third and fourth reactive groups of the first linker compound react with the free thiol groups at C186 and C201, respectively, to allow the first linker compound to react with the CRM. 197 The carrier protein residues C186 and C201 are covalently linked, thereby enabling the CRM to... 197 The carrier protein is covalently linked to the first linker.

[0119] The first linker compound can be any compound containing reactive groups (i.e., a third reactive group and a fourth reactive group), said reactive groups being capable of reacting with CRM. 197 The sulfur atoms of residues C186 and C201 of the carrier protein form a covalent link. It should also be understood that this is achieved through interaction with substances from CRM... 197 The sulfur atoms of residues C186 and C201 of the carrier protein form a covalent linker, and the first linker compound is used to rebridge CRM. 197 Reduced interchain disulfide bonds between residues C186 and C201 of the carrier protein.

[0120] Capable of combining the first linker compound with CRM 197The reactive groups attached to the sulfur atoms of carrier protein residues C186 and C201 are well known in the art. Therefore, those skilled in the art will be able to select suitable reactive groups (third and fourth reactive groups) for use in this invention. Examples of suitable reactive groups include those described in, for example, the following literature: Xu 2021 (ChemRxiv. Cambridge: Cambridge Open Engage; 2021, 1-17), Stieger 2021 (Angew. Chemie Int. Ed., 2021, 60, 1-7), Walsh 2019 (Chem. Sci., 2019, 10, 694–700), Walsh 2020 (Org. Biomol. Chem., 2020, 18, 4224–4230), Badescu 2014 (Bioconjug. Chem., 2014, 25, 1124–1136), Koniev 2018 (Medchemcomm, 2018, 9, 827–830), Robinson 2017 (RSC... Adv., 2017, 7, 9073–9077), Behrens 2015 (Mol. Pharm., 2015, 12, 3986–3998) and WO2019 / 011078.

[0121] In some embodiments, the first linker compound is a compound of the following general formula:

[0122] in: Q1 is related to CRM. 197 The first spacer group covalently linked to the carrier protein is as defined herein; RG1 is the first reactive group (e.g., azide); and W is a functional group containing a third reactive group and a fourth reactive group.

[0123] In other embodiments, the first linker compound is a compound of the following general formula:

[0124] in: n is an integer selected from 1 to 4 (e.g., 2); RG1 is the first reactive group (e.g., azide); and W is a functional group containing a third reactive group and a fourth reactive group.

[0125] Suitable, the functional group W containing the third reactive group and the fourth reactive group is selected from one of the following functional groups: , , , in: Indicates the position where the functional group W- containing the third and fourth reactive groups is attached to the remainder of the first linker compound.

[0126] In some embodiments, the third and fourth reactive groups are halide groups, such as fluorine, chlorine, bromine, or iodine groups, preferably chlorine groups.

[0127] In some preferred embodiments, the first linker compound is a compound of the following formula:

[0128] Where n is an integer selected from 1 to 4 (e.g., 2).

[0129] CRM 197 The C186-C201 disulfide bond in the carrier protein can be selectively reduced, while the C461-C471 disulfide bond remains unreduced. For example, the C186-C201 disulfide bond can be selectively reduced using TCEP.

[0130] The present invention also provides reagents and kits for generating cancer vaccine conjugates as described herein. For example, a kit for generating cancer vaccine conjugates may comprise a CRM covalently linked to a first linker. 197 Carrier protein, wherein the first linker is connected to CRM 197 The carrier protein has residues C186 and C201 covalently linked and contains a first reactive group.

[0131] Examples of salts of the compounds of the present invention (e.g., conjugates and first linker compounds) include all pharmaceutically acceptable salts, such as, but not limited to, acid addition salts of strong inorganic acids (e.g., HCl and HBr salts) and addition salts of strong organic acids (e.g., methanesulfonates). Further examples of salts include sulfates and acetates, such as trifluoroacetate or trichloroacetate.

[0132] References to the compounds described herein (e.g., conjugates and first linker compounds) also refer to solvates of those compounds. Examples of solvates include hydrates.

[0133] The compounds described herein (e.g., conjugates and first linker compounds) include compounds in which atoms are replaced by naturally occurring or non-naturally occurring isotopes. In one embodiment, the isotope is a stable isotope. Thus, the compounds described herein include, for example, deuterium-containing compounds, etc. For example, H can be in any isotopic form, including... 1 H, 2 H(D) and 3 H (T); C can be any isotopic form, including 12 C 13 C and 14 C and O can be in any isotopic form, including 16 O and 18 O; etc.

[0134] Certain compounds (e.g., conjugated compounds and first-linked compounds) may exist in one or more specific geometric, optical, enantiomeric, non-corresponding, epimeric, transisomeric, stereoisomeric, tautomeric, conformational, or anisomeric forms, including but not limited to cis-form and trans-form; E-form and Z-form; c-form, t-form and r-form; introverted and extroverted; R-form, S-form and meso-form; D-form and L-form; d-form and l-form; (+)-form and (-)-form; keto-form, enol-form and enolate-form; syn-form and anti-form; cis-transverse and transverse-transverse; α-form and β-form; axial form and equatorial form; boat-form, chair-form, torsion boat-form, envelope-form and semi-chair-form; and combinations thereof, hereinafter collectively referred to as “isomers” (or “isomeric forms”).

[0135] It should be noted that, except for the tautomerisms discussed below, the term "isomer" as used herein specifically excludes structural (or constructive) isomers (i.e., isomers that differ in the bonding between atoms, not just in the spatial positions of atoms). For example, a reference to the methoxy group OCH3 should not be interpreted as a reference to its structural isomer, the hydroxymethyl group CH2OH. Similarly, a reference to o-chlorophenyl should not be interpreted as a reference to its structural isomer, the m-chlorophenyl. However, a reference to a class of structures is likely to include structural isomers falling within that class (e.g., C...). 16 Alkyl groups include n-propyl and isopropyl; butyl groups include n-butyl, isobutyl, sec-butyl, and tert-butyl; methoxyphenyl groups include o-methoxyphenyl, m-methoxyphenyl, and p-methoxyphenyl.

[0136] Unless otherwise stated, references to specific compounds (e.g., conjugates and first linker compounds) include all such isomers, including mixtures thereof (e.g., racemic mixtures). Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallization and chromatographic techniques) of such isomers are known in the art or readily available by known means using the methods taught herein or known methods.

[0137] In some embodiments, the compounds described herein (e.g., conjugates and first linker compounds) may be in substantially purified and / or substantially contaminant-free forms.

[0138] In some implementations, the purified form is substantially at least 50% by weight, for example at least 60% by weight, for example at least 70% by weight, for example at least 80% by weight, for example at least 90% by weight, for example at least 95% by weight, for example at least 97% by weight, for example at least 98% by weight, for example at least 99% by weight.

[0139] Unless otherwise specified, substantially purified form refers to any stereoisomer or enantiomeric form of the compound. For example, in one embodiment, substantially purified form refers to a mixture of stereoisomers, i.e., purified relative to other compounds. In one embodiment, substantially purified form refers to a single stereoisomer, such as an optically pure stereoisomer. In one embodiment, substantially purified form refers to a mixture of enantiomers. In one embodiment, substantially purified form refers to an equimolar mixture of enantiomers (i.e., a racemic mixture, a racemic mixture). In one embodiment, substantially purified form refers to a single enantiomer, such as an optically pure enantiomer.

[0140] In some implementations, the pollutant represents no more than 50% by weight, for example no more than 40% by weight, for example no more than 30% by weight, for example no more than 20% by weight, for example no more than 10% by weight, for example no more than 5% by weight, for example no more than 3% by weight, for example no more than 2% by weight, for example no more than 1 ....

[0141] Unless otherwise specified, a contaminant refers to a compound other than a stereoisomer or enantiomer. In one embodiment, a contaminant refers to other compounds and other stereoisomers. In another embodiment, a contaminant refers to other compounds and other enantiomers.

[0142] In some embodiments, the purified form is substantially at least 60% optically pure (i.e., on a molar basis, 60% of the compound is the desired stereoisomer or enantiomer, and 40% is the unwanted stereoisomer or enantiomer), for example at least 70% optically pure, for example at least 80% optically pure, for example at least 90% optically pure, for example at least 95% optically pure, for example at least 97% optically pure, for example at least 98% optically pure, for example at least 99% optically pure.

[0143] The compounds of the present invention, such as the cancer vaccine conjugates described herein, can be provided in a protected form. Here, reactive functional groups (e.g., amino functional groups) can be masked to prevent their reaction during synthetic steps. Protecting groups are provided to mask the reactive functional groups, and these protecting groups can be removed in later stages of the synthesis to reveal the original reactive functional groups.

[0144] For example, the amino, hydroxyl, carboxyl, and thiol functional groups present in the conjugate can be protected by protecting groups, such as those described herein.

[0145] In one embodiment, the protected form is a compound in which amino, hydroxyl, thiol, and / or carboxyl functional groups are protected (masked) by protecting groups. In another embodiment, the protected form is a compound in which the side-chain functional groups of the amino acid residues of the compound are protected.

[0146] Protecting groups (such as those protecting amino acid residues) are well known and well described in the art.

[0147] Amino acids with side group protection (optionally along with amino and carboxyl group protection) are commercially available. Therefore, protected conjugated compounds can be prepared from suitable protected amino acid starting materials.

[0148] When using a protecting group, the protecting group can be removed without substantially disrupting the structure of the conjugate, such as without altering the stereochemistry of the amino acid residues or causing the release of the protected ortho-quinone.

[0149] In some implementations, the protecting group is acid-labile, base-labile, or removable under reducing conditions.

[0150] Examples of protecting groups for amino functional groups include Boc (tert-butoxycarbonyl), Bn (benzyl, Bzl), Cbz (Z), 2-CL-Z (2-chloro), Dde (1-[4,4-dimethyl-2,6-dioxocyclohexyl-1-ylidene]-3-methylbutyl), Fmoc (fluorenylmethoxycarbonyl), and HSO3-Fmoc (sulfonated Fmoc, such as 2-sulfonyl-Fmoc, as Schechter). et al , J.Med Chem The following are listed in 2002, 45(19) 4264): ivDde (1-[4,4-dimethyl-2,6-dioxocyclohexyl-1-yl]ethyl), Mmt (4-methoxytriphenylmethyl), Mtt (4-methyltriphenylmethyl), Nvoc (6-nitroveratroloxycarbonyl) and Tfa (trifluoroacetyl).

[0151] Examples of protecting groups for aromatic nitrogen functional groups include Boc, Mtt, Trt, and Dnp (dinitrophenyl).

[0152] In some embodiments, the protecting group of the amino functional group is selected from Boc, CbZ, Bn, and Fmoc, as well as HSO3-Fmoc.

[0153] In some implementations, the protecting group of the amino functional group is Boc, Fmoc, or CbZ.

[0154] Examples of protecting groups for the hydroxyl functional group include Trt (triphenylmethyl), Bn (benzyl), tBu (tert-butyl), and 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-galactopyranosyl.

[0155] In one embodiment, the protecting group of the amino functional group is Trt.

[0156] Further examples of protecting groups include silyl ether protecting groups (e.g., TMS, TES, TBS, TIPS, TBDMS, and TBDPS) and ethers (e.g., THP). For example, such protecting groups can be removed using TBAF.

[0157] Examples of protecting groups for carboxyl functional groups include Bn (benzyl, Bz), tBu (tert-butyl), TMSET (trimethylsilylethyl), and Dmab ({1-[4,4-dimethyl-2,6-dioxocyclohexyl-1-ylidene]-3-methylbutyl}aminobenzyl).

[0158] Examples of protecting groups for aromatic nitrogen functional groups include Boc, Mtt, Trt, and Dnp (dinitrophenyl).

[0159] In some implementations, only certain types of functional groups are protected. For example, only amino groups, such as amino groups in the side chains of amino acid residues, can be protected.

[0160] In some embodiments, the amino and hydroxyl groups are protected. The present invention also provides pharmaceutical compositions comprising the cancer vaccine conjugates described above and pharmaceutically acceptable excipients.

[0161] The method may further include mixing the cancer vaccine conjugate as described herein with a pharmaceutically acceptable excipient to produce a pharmaceutical composition.

[0162] The term "pharmaceutically acceptable" refers to compounds, materials, compositions, and / or dosage forms that, to the extent reasonably determined by veterinary or medical judgment, are suitable for contact with the tissues of an object (e.g., human or other mammal) without causing excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio. Each carrier, excipient, etc., must also be "acceptable" in the sense of compatibility with other components of the formulation.

[0163] Suitable excipients and carriers include, but are not limited to, water, saline, buffered saline, phosphate buffer, alcohol / aqueous solution, emulsion, or suspension. Other commonly used diluents, adjuvants, and excipients may be added according to conventional techniques. Such carriers may include ethanol, polyols and suitable mixtures thereof, vegetable oils, and injectable organic esters. Buffers and pH adjusters may also be used, including but not limited to salts prepared from organic acids or bases. Representative buffers include, but are not limited to, salts of organic acids, such as citrate salts (e.g., citrate derivatives), ascorbic acid salts, gluconic acid salts, carbonate salts, tartaric acid salts, succinic acid salts, acetic acid salts, phthalic acid salts, Tris salts, trimethylamine hydrochloride, or phosphate buffer. Parenteral carriers may include sodium chloride solution, Ringer's dextran, dextrose, trehalose, sucrose, lactated Ringer's solution, or fixed oil. Intravenous carriers may include fluids and nutrient supplements, electrolyte supplements, such as those based on Ringer's dextran. Preservatives and other additives, such as, for example, antibacterial agents, antioxidants, chelating agents (e.g., EGTA; EDTA), inert gases, etc., may also be provided in the drug carrier. The pharmaceutical compositions described herein are not limited by the choice of carrier. The preparation of these pharmaceutically acceptable compositions from the components described above is within the scope of the art and has suitable pH, isotonicity, stability, and other conventional characteristics.

[0164] Suitable carriers, excipients, etc. can be found in standard pharmaceutical textbooks, for example, Remington's Pharmaceutical Sciences and The Handbook of Pharmaceutical Excipients, 4th edit., eds. RC Rowe et al, APhA Publications, 2003.

[0165] The pharmaceutical compositions of the present invention may be vaccine compositions. The pharmaceutical compositions or vaccine compositions may further comprise adjuvants.

[0166] Adjuvants are compounds that enhance or amplify the immune response to immunogenic compounds. Suitable adjuvants for vaccine compositions include, but are not limited to, inorganic compounds (e.g., aluminum salts), oils, bacterial products (e.g., toxoids), and cytokines (e.g., IL-1 and IL-2). Other suitable adjuvants include squalene-based oil-in-water nanoemulsions, such as MF-59 and AddaVax™.

[0167] Vaccine and pharmaceutical compositions can be conveniently presented in unit dosage forms and can be prepared by any method well-known in the pharmaceutical industry. Such methods include the step of associating one or more isolated conjugates / immunogenic peptides with a carrier or excipient as described above, which may constitute one or more auxiliary components. Typically, formulations are prepared by homogeneously and tightly associating an active compound with a liquid carrier or a fine solid carrier, or both.

[0168] Vaccine and pharmaceutical compositions can be prepared in the form of sterile aqueous solutions or dispersions suitable for injection, or in lyophilized form using freeze-drying technology. Lyophilized pharmaceutical compositions are typically maintained at about 4°C and can be reconstituted in stable solutions (e.g., saline or HEPES), with or without adjuvants.

[0169] Vaccine and pharmaceutical compositions can be contained in single-dose or multi-dose sealed containers (e.g., ampoules and vials) and can be stored under lyophilized conditions, requiring only the addition of a sterile liquid carrier (e.g., water) before use for immediate injection. Vaccine and therapeutic compositions according to the invention can be formulated for administration via a variety of routes, including but not limited to parenteral, intravenous, intra-arterial, intramuscular, intratumoral, oral, and nasal administration.

[0170] Cancer vaccine conjugates containing immunogenic glycopeptides linked to the CRM197 peptide described herein can be internalized by B cells and can be used, for example, to generate B cell and T cell-mediated immune responses against immunogenic glycopeptides.

[0171] This document also provides methods for stimulating an immune response in a subject, wherein the methods include administering the conjugates or pharmaceutical compositions described herein to a subject in need; and the conjugates or pharmaceutical compositions described herein for use in such methods.

[0172] Immune responses include B cell-mediated immune responses and T cell-mediated immune responses.

[0173] This article also provides methods for treating cancer, including administering the cancer vaccine conjugates or pharmaceutical compositions described herein to individuals in need; cancer vaccine conjugates or pharmaceutical compositions described herein or used for treating cancer; and the use of the cancer vaccine conjugates or pharmaceutical compositions described herein in the manufacture of a medicament for treating cancer.

[0174] Cancer is characterized by the abnormal proliferation of malignant tumor cells. Cancer can be any type of cancer, including leukemia (e.g., AML, CML, ALL, and CLL), lymphoma (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma), and multiple myeloma, as well as solid cancers such as sarcoma, skin cancer, melanoma, bladder cancer, brain cancer (e.g., glioma), breast cancer (e.g., triple-negative breast cancer and metastatic breast cancer), uterine cancer, oral cancer, ovarian cancer, prostate cancer, lung cancer, colorectal cancer (e.g., colon cancer), cervical cancer, liver cancer, head and neck cancer, esophageal cancer, pancreatic cancer, kidney cancer, adrenal cancer, stomach cancer, testicular cancer, gallbladder and bile duct cancer, thyroid cancer, thymic cancer, neuroblastoma, bone cancer, and cerebral cancer. In some preferred embodiments, the cancer can be pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, lung cancer, gallbladder cancer, or colorectal cancer.

[0175] Cancer cells suitable for the treatment described herein may express tumor antigens that are recognized by an immune response triggered by immunogenic peptides of cancer vaccine conjugates.

[0176] Suitable tumor antigens are known in the art and include mucin-1 (MUC1). Cancer cells suitable for the treatment described herein can overexpress MUC1. For example, cancer cells can express 1.5 times or more, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more, or 10 times or more MUC1 compared to normal cells. Cancer cells suitable for the treatment described herein can express MUC1 with aberrant glycosylation. For example, aberrantly glycosylated MUC1 can be recognized by an immune response induced by an immunogenic glycopeptide containing the epitope of SEQ ID NO: 1.

[0177] Individuals who are to be treated with the cancer vaccine conjugates or pharmaceutical compositions described herein may be mammals, such as rodents (e.g., guinea pigs, hamsters, rats, mice), rodents (e.g., mice), canines (e.g., dogs), felines (e.g., cats), equines (e.g., horses), primates, apes (e.g., monkeys or apes), monkeys (e.g., marmosets, baboons), apes (e.g., gorillas, chimpanzees, orangutans, gibbons), or humans.

[0178] In some preferred embodiments, the individual is a human. In other preferred embodiments, non-human mammals may be used, particularly mammals commonly used as models for representing therapeutic efficacy in humans (e.g., rodents, primates, pigs, canines, or rabbits).

[0179] In some implementations, individuals may have minimal residual disease (MRD) after initial cancer treatment.

[0180] An individual with cancer may exhibit at least one identifiable sign, symptom, or laboratory finding sufficient to make a diagnosis of cancer according to clinical criteria known in the art. Examples of such clinical criteria can be found in medical textbooks, such as Harrison's Principles of Internal Medicine, 15th Ed., Fauci AS et al., eds., McGraw-Hill, New York, 2001. In some cases, the diagnosis of cancer in an individual may include identifying a specific cell type (e.g., cancer cells) in a sample of bodily fluids or tissues obtained from the individual.

[0181] The term "treatment," as used in the context of treating a condition, generally refers to treatments and therapies that achieve some desired therapeutic effect, such as inhibiting the progression of the condition and including reducing the rate of progression, stopping the rate of progression, and improving or curing the condition.

[0182] Treatment can be any treatment or therapy (whether in humans or animals (e.g., in veterinary applications)) that achieves some desired therapeutic effect, such as inhibiting or delaying the progression of a disease, including reducing the rate of progression, stopping the rate of progression, improving the condition, curing or alleviating the condition (whether partially or completely), preventing, delaying, reducing or suppressing the symptoms and / or signs of one or more conditions, or prolonging the life of a subject or patient beyond their expected life in the absence of treatment.

[0183] This also includes treatments as a preventative measure (i.e., prevention). For example, individuals susceptible to cancer or at risk of developing or recurring cancer can be treated as described herein. Such treatments can prevent or delay the onset or recurrence of cancer in an individual. Therefore, the cancer vaccine conjugates and pharmaceutical compositions described herein can be used for therapeutic treatment of individuals with cancer or for preventative treatment of individuals to prevent or delay the onset or recurrence of cancer.

[0184] Specifically, treatment may include inhibiting cancer growth, including achieving complete remission of cancer and / or inhibiting cancer metastasis. Cancer growth generally refers to any one of several indicators that indicate cancer is changing into a more advanced form. Therefore, indicators used to measure inhibition of cancer growth include decreased cancer cell survival, reduction in tumor volume or morphology (e.g., as determined using computed tomography (CT), ultrasound, or other imaging methods), delayed tumor growth, disruption of the tumor vascular system, improved performance on delayed-type hypersensitivity skin tests, increased activity of cytolytic cancer cells, and reduced levels of tumor-specific antigens.

[0185] In some preferred embodiments, a therapeutic agent (such as the cancer vaccine conjugate or pharmaceutical composition described herein) can be administered to an individual without the need for other accompanying cancer therapies (such as cytotoxic chemotherapy or radiation therapy), i.e., the therapeutic agent can be administered alone.

[0186] In other embodiments, the cancer vaccine conjugates or pharmaceutical compositions described herein may be administered in combination with one or more other therapies, such as cytotoxic chemotherapy or radiotherapy.

[0187] When a therapeutic agent is used in combination with another therapeutic agent, the compounds may be administered sequentially or simultaneously via any convenient route. When a therapeutic agent is used in combination with another therapeutic agent effective against the same disease, the dosage of each agent used in combination may differ from that when the therapeutic agent is used alone. Those skilled in the art will readily understand the appropriate dosage.

[0188] In some preferred embodiments, the cancer vaccine conjugates or pharmaceutical compositions described herein may be administered in combination with immune checkpoint inhibitors.

[0189] Immune checkpoint inhibitors are agents that inhibit cell signaling mediated by immune checkpoint molecules. Immune checkpoint molecules can include PD-1, CTLA-4, LAG-3, TIM-3, TIGIT, and BTLA. Immune checkpoint inhibitors have been reviewed in the following literature: for example, Darvin P et al., Experimental & Molecular Medicine, 2018, 50:165; de Miguel M & Calvo E, Cancer Cell, 2020, 38:326; and Marin-Acevedo JA et al., J Hematol Oncol. 2021, 14:45. Suitable immune checkpoint inhibitors are available in the art and include, for example, ipilimumab, tremelimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and dostarlimab.

[0190] In some embodiments, the immune checkpoint inhibitor can inhibit PD-1-mediated cell signaling. The agent can be a PD-L1 target, or more preferably a PD-1 target. For example, the agent can be an antibody that specifically binds to PD-L1, or more preferably specifically binds to PD-1 and inhibits PD-1-mediated signaling. In some embodiments, the agent can be an anti-PD-L1 antibody or a fragment thereof (e.g., an antagonist anti-PD-L1 antibody or a fragment thereof), or an anti-PD-1 antibody or a fragment thereof (e.g., an antagonist anti-PD-1 antibody or a fragment thereof). Suitable anti-PD1 antibodies include nivolumab, pembrolizumab, dotalimab, and cimiprimab. Suitable anti-PD-L1 antibodies include atezolizumab, avelumab, and durvalumab.

[0191] The administration of the cancer vaccine conjugates or pharmaceutical compositions described herein can be achieved continuously or intermittently (e.g., in fractionated doses at appropriate intervals) throughout the treatment process. Methods for determining the most effective means of administration and dosage are well known to those skilled in the art and will vary depending on the formulation used in the therapy, the purpose of the therapy, the target cells of the treatment, and the patient being treated. Single or multiple administrations can be performed at dosage levels and in patterns chosen by the treating physician.

[0192] Other aspects and embodiments of the invention provide for aspects and embodiments described above in which the term "comprising" is replaced by the term "consisting of," and in aspects and embodiments described above in which the term "comprising" is replaced by the term "substantially constitutes."

[0193] It should be understood that, unless the context otherwise requires, this application discloses all combinations of any of the foregoing aspects and embodiments and each other. Similarly, this application discloses, individually or in conjunction with any other aspect, all combinations of preferred and / or optional features, unless the context otherwise requires.

[0194] Modifications to the above-described embodiments, further embodiments, and modifications thereof will be apparent to those skilled in the art upon reading this disclosure; therefore, such modifications, further embodiments, and modifications thereof are within the scope of this invention.

[0195] All files and sequence database entries mentioned in this specification are incorporated herein by reference in their entirety for all purposes.

[0196] As used herein, “and / or” shall be regarded as a specific disclosure of each of two specified features or components together or apart from the other. For example, “A and / or B” shall be regarded as a specific disclosure of (i) A, (ii) B and (iii) each of A and B as if each were listed separately herein.

[0197] experiment

[0198] Materials and methods

[0199] Synthesis of glycopeptide 1'.

[0200] The synthesis was performed automatically using Rink Amide MBHA resin (0.05 mmol) and an automated synthesizer. Glycosylated amino acid building blocks (2.0 equivalents) were synthesized as described in the literature (24). This residue and the cyclooctyne derivative were manually coupled using HBTU [(2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylurea hexafluorophosphate], while using oxyma pure / DIC ( N, N’(-Diisopropylcarbodiimide) was automatically coupled to other fluorenylmethoxycarbonyl (Fmoc) amino acids (5.0 equivalents). Fmoc deprotection was performed using a 20% (v / v) piperidine solution in dimethylformamide (DMF). The o-acetyl groups of the glycosides were deprotected using 5 mL (3 × 15 min) hydrazine / MeOH (7:3) solution. During synthesis, the glycopeptide 1' was desorbed from the resin and all acid-sensitive side-chain protecting groups were simultaneously removed using 95% TFA, 2.5% TIS (triisopropylsilane), and 2.5% H2O, followed by precipitation with cold diethyl ether. The crude glycopeptide was purified by semi-preparative HPLC on a Phenomenex Luna C18(2) column (10 μ, 250 mm × 21.2 mm) with a dual absorbance detector at a flow rate of 10 mL / min or 20 mL / min.

[0201] CRM 197 Synthesis of Linker-Azides

[0202] 20 mg of 1,3-dichloropropanone (0.16 mmol) was reacted with 40 mg of aminooxy-PEG3-azide (0.17 mmol, 1.1 equivalents) in 1 mL of DMF at 21 °C for 24 h. The reaction product was then purified by silica gel column chromatography by applying a gradient of ethyl acetate in ethane (40% to 100%), followed by 20% ethyl acetate in methanol and 100% methanol. A total of 13 mg of compound 2 (0.04 mmol, 25% yield) was obtained, and a stock solution of 40 mM in DMF was prepared. CRM was then reduced with 12 equivalents of TCEP. 197 : 5 μL of 47 mg / mL CRM at 21℃ 197 The stock solution of compound 2 (final concentration 40 μM) and 2.4 μL of 6 mg / mL TCEP stock solution were mixed in PBS pH 7.4 (final volume 99 μL). After stirring for 2 h, the protein was mixed with 20 equivalents of compound 2 (2 μL of 40 mM compound 2 solution) at 21 °C for 5 days. The resulting modified protein was then centrifuged using a Zeba column (for replacing the buffer with H2O) and analyzed by LC-MS.

[0203] CRM 197 -The synthesis of connector-1'. 20 μL of CRM 197The linker-azide (41 μM in PBS) was incubated with 8.5 μL of derivative 1' (10 mg / mL, 20 equivalents in PBS) at 25 °C for 20 h. Finally, the reaction mixture was purified on a Zeba column and analyzed by mass spectrometry, SDS-PAGE, and Western blotting.

[0204] Circular dichroism (CD) spectroscopy

[0205] Proteins were desalted using a PD-minitrap G25 column (according to the manufacturer's instructions) and further used with 5 µM (in pH 7.4 PBS buffer). Far-ultraviolet circular dichroism (CD) data were obtained using 1.0 mm quartz cuvettes (Hellma GmbH & Co, Müllheim, Germany) on a Jasco J-815 CD spectropolarimeter (Hachioji, Tokyo, Japan). All spectra from 195 nm to 300 nm were collected at 25 °C with a sampling rate of 200 nm·min. -1 The data interval was 0.5 nm, the data integration time was 1 s, and the bandwidth was 1 nm. Each spectrum represents the average of 5 scans. Absorption spectra were also monitored to control for light scattering and signal detection saturation. In addition to blank subtraction, instrument-related baseline drift was corrected by subtracting the average signal from 250 nm to 260 nm from each spectrum. The original ellipticity θ was then converted to molar ellipticity ([θ]; expressed in deg·cm). 2 ·dmol -1 (Calculation). All conditions were measured independently and repeated twice.

[0206] Mass spectrometry analysis

[0207] Modified proteins were analyzed by liquid chromatography-mass spectrometry (LC-MS). Protein LC-MS was performed on a Waters Acquity UPLC system equipped with a QDa single quadrupole mass detector. Separation was based on an Xbridge BEH C4 column (Waters, 3.5 μm, 300 Å pore size, 2.1 × 100 mm) maintained at 40 °C. Solvents A (0.1% v / v formic acid in redistilled water) and B (0.01% v / v formic acid in acetonitrile) were used as mobile phases. The gradients of solvents A and B were applied as follows: 10% B for 5 min, followed by a slow gradient increase to 100% B over 15 min. B was restored to 10% at 20.1 min and maintained above that percentage for 7.9 min to recover the LC column. The total run time was 28 min at a flow rate of 0.2 mL / min. The electrospray source was operated at a capillary voltage of 1.5 kV and a cone voltage of 20 V. Nitrogen was used as the desolvation gas at a total flow rate of 800 L / h and a cone-volume flow rate of 1 L / h. The desolvation temperature was set to 400°C. The total mass spectrum was reconstructed from the ion series using the MaxEnt algorithm pre-installed on MassLynx software (version 4.1, from Waters). To obtain the ion series, protein peaks from the chromatographic spectrum were selected for integration and further analysis.

[0208] SDS-PAGE

[0209] By using non-reducing conditions, the conjugate, WT CRM 197 The conjugate was validated by running the glycopeptide 1' in a 12% acrylamide gel in Tris-Glycine / SDS run buffer (25 mM Tris base, 190 mM glycine, 0.1% SDS, pH 8.3) at 100V for 1.5 h. PageRuler pre-stained protein molecular weight standards were used as molecular markers. The gel was further prepared for SDS-PAGE analysis by staining with InstantBlue Coomassie Protein Stain from Abcam (according to the manufacturer's instructions).

[0210] Molecular dynamics (MD) simulations

[0211] CRM 197The crystal structure was used as the starting coordinates of the protein (25). Notably, although the protein presents only one copy of the glycopeptide 1', up to four possible isoforms (Z-oxime / E-oxime and 1,4-triazole adduct / 1,5-triazole adduct) can be expected. The different isoforms were simulated using the AMBER 20 software package (36) with force fields implemented using ff14SB (37) and gaff2 (38). The topology and coordinate files for MD simulations were generated using the LEaP module of AMBER 20, and MD simulations were performed using the CUDA version of the PMEMD module of the AMBER simulation software package. Each conjugate was immersed in a water tank with a 10 Å buffer containing TIP3P water molecules (39) and subjected to the addition of an explicit anti-charge ion (Na+). + Neutralization. A two-stage geometric optimization method was performed using the PMEMD module. The first stage used 50 kcal·mol· -1 ·Å -2 The harmonic potential is minimized only with respect to the positions of solvent molecules and ions, and the second stage is an unrestricted minimization of all atoms in the simulation unit. In both stages, a steepest descent minimization is performed over 2500 steps, followed by a conjugate gradient minimization over 2500 steps. The system is then heated by increasing the temperature from 0 to 300 K under constant pressure of 1 atm and periodic boundary conditions of 2 ns. A solute is treated with 10 kcal·mol⁻¹. -1 Harmonic suppression was achieved, and the temperature was controlled and balanced using the Andersen temperature coupling scheme (40). The time step during the heating phase was maintained at 1 fs. The SHAKE algorithm was applied to constrain all bonds involving hydrogen atoms (41). Long-range electrostatic effects were simulated using the particle-mesh Ewald method (42). A sharp cutoff of 8 Å was applied to the Lennard-Jones interaction. Each system was balanced for 2 ns at a time step of 2 fs under constant volume and 300 K conditions. Production trajectories were then run for an additional 0.5 µs under the same simulation conditions.

[0212] MUC1.Tg mouse genotyping

[0213] MUC1.Tg breeding pairs were purchased from Jackson Laboratories and bred at the iMM-JLA animal facility. Ear samples were collected from pups by animal facility technicians. The samples were then used for gDNA extraction via the NaOH gDNA extraction method. Briefly, the samples were incubated with 75 μL of alkaline lysis reagent at 95°C for 1 h. After incubation, the samples were vortexed and 75 μL of neutralization reagent was added. The samples were centrifuged at 4000 rpm for 3 min, and 2 μL of the sample was immediately used for PCR. The PCR reaction was performed using primers and Taq DNA polymerase (recombinant) (5 U / µL) from ThermoScientific. The reaction mixture consisted of: 2.5 μL of 10X buffer with KCl, 1 μL of primers, 1 μL of 25 mM MgCl2, 0.5 μL of a 10 mM dNTP mixture, 2 μL of template DNA, 0.25 μL of Taq, and water (up to 25 μL). The reaction conditions were: (1) 95℃ for 3 min, (2) 95℃ for 30 s, (3) 60℃ for 30 s, (4) 72℃ for 1 min (40 cycles of steps 2 to 4), and 72℃ for 10 min. The results from the PCR reaction were confirmed by agarose gel electrophoresis (2% gel). PCR was considered positive when two bands appeared (transgenic and internal control), and negative when only one band appeared (internal control).

[0214] Mouse immunization regimen

[0215] 12- to 14-week-old MUC1.Tg mice (housed indoors) expressing human MUC1 at physiological levels received four intraperitoneal injections (IP) of the vaccine candidate at 21-day intervals. A total of three groups of mice (n=5 per group) were used: CRM 197 -Linker-1' (total 2 μg MUC1) - Group 1; CRM 197 (47 μg protein, same injection volume as Group 1) – Group 2; PBS – Group 3. Mice were injected with a total of 100 µL of Addavax (50 µL adjuvant + 50 µL vaccine candidate) as part of the formulation. Blood samples were collected via buccal puncture before immunization and 5 days after each booster immunization, and whole blood was collected via cardiac puncture 5 days after the final booster immunization. Serum was recovered from the blood by centrifugation (4 min, 4000 rpm). The immunized mice were further used to attack tumors with MC38-MUC1 cells.

[0216] Antibody titers were determined by ELISA analysis.

[0217] Use non-natural glycopeptide 1' or CRM to test 96-well Maxisorb ELISA plates (Nunc). 197 The plates were coated with coating buffer (4°C, overnight). After blocking with ELISA blocking buffer, the plates were incubated with 1:100 dilutions of serum from the first and second blood collections, compared to pre-immunization serum. Binding antibodies were detected using anti-mouse secondary antibodies IgG HRP (Invitrogen, 1:3000), IgG1-HRP (1:1000, eBioscience), IgG2a-HRP (1:50,000, Abcam), IgG2b-HRP (1:50,000, Abcam), IgG3-HRP (1:50,000), and IgM-HRP (1:50,000, Abcam). All incubations were performed at 25°C for 1 h, with three washes with ELISA washing buffer between incubations. The assay was performed by incubation at 25°C for 10 min with TMB 1x solution (eBioscience) for color development. The TMB kinetic reaction was stopped using the ELISA stop solution, which caused the solution color to change from blue to yellow, making it possible to read the absorbance at 450 nm using an Infinite M200 microplate reader. Background absorbance values ​​(absorbance obtained from wells incubated only with secondary antibody – blank) were subtracted before presenting the raw data.

[0218] Tumor induction in mice

[0219] By administering 1×10⁻⁶ immunizations 6 days after the last immunization. 6 MC38-MUC1 cells (commercially available at Kerafast) were subcutaneously inoculated into the flanks of mice to establish a local colon cancer model in immunized MUC1.Tg mice. Tumor growth was monitored over time by bilateral caliper measurements every 3 days and by calculating the mean tumor volume using the formula (length × width 2) / 2. Animals were euthanized on day 15 post-tumor induction for the collection of serum, tumor, spleen, and draining lymph nodes. No signs of suffering or discomfort were observed in the animals, including no weight loss. The collected data were analyzed using GraphPad Prism8.

[0220] Cytokine and chemokine level measurement

[0221] Cytokine levels in the serum of immunized mice were measured using the Mouse High Sensitivity T-Cell Discovery Array 18-plex (MDHSTC 18) assay from Eve Technologies. This assay allows for the quantification of the following cytokines: GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12 (p70), IL-13, IL-17A, KC / CXCL1, LIX, MCP-1, MIP-2, and TNF-α.

[0222] T cell isolation for flow cytometry and CTL assay

[0223] Mice were euthanized by isoflurane overdose, and tumors, inguinal lymph nodes (iLNs), and spleens were collected for T-cell isolation. While the iLNs and spleens were homogenized using a 100 μm cell filter and diluted in 2 mL and 8 mL of DMEM complete medium (containing 0.05 mM 2-mercaptoethanol), respectively, the tumors were dissected into small pieces (in 5 mL tubes) and incubated at 37°C, 220 rpm for 30 min with 1 mL of digestion medium (0.4 mg / mL collagenase I, 1 mg / mL collagenase IV, and 10 µg / mL DNase I). After digestion, the cell suspension was diluted in 4 mL of ice-cold DMEM complete medium, filtered through a 100 µm cell filter, and centrifuged at 500 x g for 5 min. The cell pellet was incubated with 1 mL of erythrocyte lysis buffer and immediately centrifuged at 500 x g for 5 min. At this point, the cell pellet is resuspended in 2 mL of complete DMEM and counted for staining or cytotoxic T lymphocyte (CTL) assays.

[0224] T cell staining was measured by flow cytometry.

[0225] Approximately 2×10 6Cells were transferred to 96-well round-bottom plates and centrifuged at 500x g for 3 min to remove supernatant. The cell pellet was incubated on ice for 10 min with 20 µL of Fc Block (1:100) in FACS buffer. After washing the cells with 100 µL of FACS buffer and centrifuging (as previously described), the cells were incubated on ice for approximately 45 min with 20 µL of an extracellular antibody mixture. The extracellular antibody mixture consisted of CD62L-FITC (1:500), CD44-PE (1:500), CD4-APC (1:500), CD45-BV510 (1:100), CD8a-SB600 (1:500), and CD3-BV711 (1:100). 7aad activity dye (5 µL / 1×10⁻⁶) was also added. 6 (Number of cells) were used to determine live cells. Samples were obtained using BD LSR Fortessa and analyzed using FlowJo (version 6.3.4).

[0226] Magnetic activated cell sorting (MAC) for isolating T cells from the spleen

[0227] After lysing and passing through a 100 μm cell filter, splenocytes were centrifuged at 500 x g for 5 min. The cell pellet was incubated with erythrocyte lysis buffer and immediately centrifuged again (500 x g, 5 min). The supernatant was removed, and the cell pellet was incubated on ice for 15 min with anti-CD3-APC antibody (1:100 in MACS buffer). After incubation, the cells were washed with MACS buffer and centrifuged (5 min, 500 x g). After removing the supernatant, the cells were mixed with APC nanobead solution (1:10 µL, approximately 10 µL / 10⁻⁶). 7 Cells were incubated on ice for 15 min. After this incubation, the cells were washed with MACS buffer (centrifuged at 500 x g for 3 min). The supernatant was removed, and the cells were resuspended in 2.5 mL of MACS buffer and placed on a magnetic rack for 5 min. Unlabeled fractions were discarded, and the ligation fractions were resuspended in 2.5 mL of MACS buffer and the tube was placed back on the magnetic rack. This step was repeated once more (for a total of 3 times). After the final step, the cells were counted and used for CTL assays.

[0228] Cytotoxic T lymphocyte assay (CTL)

[0229] To determine CTL activity, MC38-MUC1 and MC38 cells were used in combination with T cells isolated from the spleens of immunized mice. MC38-MUC1 and MC38 cells were cultured according to the production quotient instructions (complete DMEM was used for MC38 cells, and complete DMEM containing gentamicin and genistein antibiotics was used for MC38-MUC1 cells). Cells were seeded at 10,000 cells per well and allowed to adhere for 24 h. T cells isolated from mice were then added at effector-to-target ratios of 3:1, 10:1, and 90:1 (T cells:cancer cells). Cell viability was determined after 24 h using CellTiter Blue (Promega) and an M200 microplate reader. Cytotoxicity was calculated as the percentage of live cells in the presence of T cells relative to the percentage of cells in the absence of T cells.

[0230] Serum-bound flow cytometry analysis

[0231] The CRM was determined by flow cytometry analysis. 197 - Binding affinity of the antibody generated by the linker-1' vaccine candidate. Briefly, T47D cells (human breast cancer cells highly expressing TA-MUC1) and HEK293T cells (not expressing human TA-MUC1) were fixed for 10 min with ice-cold solution of 4% paraformaldehyde. After fixation, the cells were permeabilized with 0.1% Triton-X 100 PBS solution for 15 min, followed by a blocking step with 10% FBS PBS solution for 30 min. Cells were then incubated with mouse serum diluted 1:50, followed by incubation with a secondary antibody from Abcam: goat anti-mouse polyclonal IgG H&L Alexa Fluor 488 (1:2000). All incubation steps were performed at 25°C for 1 h, followed by a washing step with PBS. Samples were acquired using a BD LSR Fortessa set with a 488 nm laser and a 530 / 30 nm bandpass filter (used in combination with Alexa 488 detection) and analyzed using FlowJo (version 6.3.4).

[0232] result

[0233] The previously studied non-natural glycopeptide 1 (24) (Figure 1) is equipped with a cyclooctyne moiety at the N-terminus to selectively introduce CRM. 197 Azide group reaction of proteins (see below). CRM was treated with excess tris(2-carboxyethyl)phosphine (TCEP) at 25°C. 197 2 h allows us to selectively reduce the C186-C201 bonds ( Figure 2a) (29). The resulting protein was then reacted with 20 equivalents of compound 2 (Materials and Methods) in PBS buffer (pH 7.4) at 21°C for 5 days to obtain the desired modified protein (CRM) after purification using a Zebra column. 197 -Linker-azide, Figure 2 b). Liquid chromatography-mass spectrometry (LC-MS) analysis showed a single peak at 58705 Da, corresponding to a disulfide modification and subsequent re-bridging to introduce an azide handle. Figure 2 (b).

[0234] The installation of compound 2 into CRM was studied using circular dichroism. 197 The impact of (CD, Figure 2 c). We observed CRM 197 -Linker-azide CD spectrum and CRM 197 The CD spectra (29, 30) were the same, indicating that the secondary structure was maintained after selective chemical modification of the indicator sites.

[0235] Subsequently, the conjugate CRM was treated with glycopeptide 1' at 25°C. 197 -Linker-azide (1:20 protein / glycopeptide ratio) 20h ( Figure 3 (a). The reaction mixture was then purified on a Zebra column and analyzed by LC-MS (a). Figure 3 b), this confirms homogeneous CRM 197 - Successful conjugation and formation of linker-1'. Molecular dynamics (MD) simulations of this conjugate showed that the addition of the glycopeptide did not alter the 3D structure of the protein. Figure 3 (c).

[0236] These calculations also demonstrate the flexibility of the linker and how it facilitates the exposure of the glycopeptide (antigen) to the solvent. Notably, although the protein displays only one copy of the glycopeptide 1', up to four possible isoforms can be anticipated (Z-oxime / E-oxime and 1,4-triazole adduct / 1,5-triazole adduct). The conjugation procedure is suitable for scale-up and can produce a homogeneous vaccine, CRM, for immunization studies in mice. 197 -connector-1'.

[0237] Then we tested the CRM. 197 Immunogenic potential of linker-1' in mice. For this purpose, a group of five MUC1.Tg mice were immunized with an initial dose of the vaccine candidate, followed by three booster doses of the vaccine candidate (21 days apart), while a control group received unconjugated CRM. 197The mice were treated with one control group and treated with phosphate-buffered saline (PBS) alone. Serum from immunized mice was collected 5 days after each injection to examine the level of anti-MUC1 antibodies. Figure 4 (a). Therefore, ELISA analysis was performed using glycopeptide 1 (Figure 1) loaded onto plates. Figure 4 As shown in b, anti-MUC1 antibodies were detected after the second injection. Higher antibody titers were observed after the third and fourth immunizations, indicating a booster effect. Importantly, the antibodies induced in mice by our vaccine candidate were primarily IgG antibodies (…). Figure 4 b and Figure 4 c), while the level of IgM antibody was significantly lower ( Figure 4 (d). This result indicates a mature immune response accompanying class switching recombination. Further examination of IgG antibodies with an additional ELISA assay was performed to determine their isotype ( Figure 4 (c) When all IgG isotypes were detected, the triggering antibody was primarily IgG2, indicating that the vaccine triggered a Th1 response. Notably, a response against CRM was also observed. 197 Antibodies.

[0238] We then examined whether the generated antibodies could recognize human tumor-associated MUC1 (TA-MUC1) overexpressed in cancer cells. Therefore, serum from immunized mice was incubated with T47D (33) cells (used as a positive control) and HEK293T (34) cells (used as a negative control), and binding was assessed by flow cytometry. These experiments showed that the antibodies generated by our vaccine were able to bind to T47D cells expressing TA-MUC1 on their surface. In contrast, negligible binding was observed in HEK293T cells, consistent with the absence of MUC1 on their surface (comparative). Figure 4 e and Figure 4 f).

[0239] In proving CRM 197 After the -linker-1' vaccine produced antibodies that selectively recognize human TA-MUC1, we next evaluated the ability of these antibodies to promote cancer prevention. For this purpose, tumors were induced in immunized mice by inoculating them with MC38-MUC1 cells 6 days after the last injection. We used the MC38-MUC1 cell line, which was derived from mouse colon adenocarcinoma further engineered to express human MUC1 (35). Tumor growth was tracked until day 15, after which the study mice were sacrificed. Compared with CRM 197 Or, as a control group immunized with PBS, it was observed that CRM was used. 197 Tumor growth is delayed in animals immunized with linker-1'. Figure 5 a and Figure 5(b) Compared to the control, the tumor size in the treated mice was reduced by approximately 55% by day 15. Furthermore, one mouse in the treatment group did not develop a detectable tumor for up to 15 days after tumor cell inoculation.

[0240] The levels of circulating cytokines following tumor induction were also evaluated. Notably, elevated levels of Th1-related cytokines (such as IL-2, IFN-γ, and TNF-α) were detected. Figure 5 (c) but no significant amounts of Th2-related cytokines (e.g., IL-4, IL-10, and IL-13) were observed. Figure 5 (d). This confirms that the immune response triggered by the vaccine candidate is a Th1-type response, as indicated by the isotype of IgG detected in serum ( Figure 4 (c).

[0241] We also evaluated the effectiveness of T cells in promoting cytotoxic T lymphocyte (CTL) responses. Briefly, CD3+ was isolated from the spleens of mice in both the treatment and control groups. + T cells (including CD4) + T cells and CD8 + T cells (Materials and Methods) were used for CTL assays. Interestingly, when MC38-MUC1 cells were used with CRM... 197 When T cells isolated from mouse spleens treated with linker-1' were co-cultured, the viability of MC38-MUC1 cells was observed to be approximately 20% lower than that of cells obtained from the control group. Figure 5 (e). This experiment demonstrates that T cells from the treatment group can recognize tumor-associated MUC1 expressed in MC38-MUC1 cells, thereby inducing cancer cell death. Therefore, CRM 197 -Linker-1' can slow tumor proliferation and potentially enhance the activity of cytotoxic T cells against cancer cells expressing human TA-MUC1, along with other factors.

[0242] In the final phase of our study, we conducted pivotal experiments to evaluate the effectiveness of our homogeneous conjugate as a potential therapeutic vaccine in reducing tumor growth. Figure 5 (f). To achieve this, we induced tumors (MC38-MUC1 cells or Panc02-MUC1 cells) in mice that had not previously been treated with the vaccine. The MC38-MUC1 cell line represents mouse colonic adenocarcinoma expressing TA-MUC1 on its surface. The Panc02-MUC1 cell line corresponds to a mouse pancreatic cancer model expressing the human MUC1 sequence on its surface. When the average tumor size reached 100 mm... 3 When starting to use CRM 197 -Connector-1' Processing. Processing begins with CRM.197 -Connector-1' as a standalone therapy ( Figure 5 f and Figure 6 ) or in combination with checkpoint inhibitors ( Figure 7 Mice were administered four times at two-day intervals, the same as those administered in previous in vivo studies. Mice were closely monitored until the tumor size reached 1000 mm. 3 Mice were euthanized for analysis.

[0243] The results of this experiment are promising, as all mice treated with the vaccine survived beyond day 10, while untreated mice were euthanized due to tumor size. In the MC38-MUC1 cancer model, tumor size decreased by approximately 40% by day 7 in treated mice, while in the Panc02-MUC1 model, tumor size decreased by approximately 75% by day 25 (the day when the first control animal reached the endpoint) (see [references]). Figure 5 b and Figure 6 Regarding survival probability, all vaccine-treated mice in the MC38-MUC1 model survived beyond day 10, compared to untreated mice whose tumors reached 1000 mm on day 10. 3 Until day 15, the survival rate of the treated mice was approximately 40%. Figure 5 (f). Although tumors typically grow slowly in the Panc02-MUC1 model, similar results were observed, with delayed tumor growth and prolonged survival in treated animals compared to controls. In this case, the survival rate of treated mice on day 54 was 25% (f). Figure 6 (See right figure). These results indicate that our homogeneous vaccine has the potential therapeutic effect on tumor growth, as demonstrated by prolonged survival.

[0244] We combined our homogeneous vaccine with a checkpoint inhibitor to investigate the combined effect of the two treatments in a single therapeutic formulation. In this combination therapy, the same subcutaneous (SC) dose of the vaccine was administered four times at two-day intervals, regardless of the cancer cell line used. Figure 7 Anti-PD1 antibody was administered via three intraperitoneal (IP) injections at 3-day intervals, with IgG2a isotype antibody used as a control. Mice were closely monitored, and tumor size was increased to 1000 mm. 3 Mice were then sacrificed. Notably, this therapy resulted in a significant reduction in tumor size. In the MC38-MUC1 cancer model, tumor size in the treated mouse group was reduced by approximately 70% on day 10 (when the first control mouse reached the endpoint) compared to PBS-treated mice. Furthermore, CRM... 197Mice treated with linker-1' and anti-PD1 had a survival rate of approximately 80% on day 20. Notably, one mouse showed complete tumor regression by day 65 (when it was euthanized). Figure 7 (See the image above). Similar results were obtained in the pancreatic cancer model. In this case, in mice treated with the combination therapy, tumor growth was reduced by approximately 84% on day 25 (the day the first control animal died), and more than 20% of the mice survived to day 60. Figure 7 (See the image below).

[0245] In summary, we have, for the first time, produced a homogeneous cancer vaccine based on a substitute for a MUC1-like glycopeptide containing non-natural fluorinated proline and a Tn antigen with an S-glycosidic bond. This antigen and protein CRM 197 Selective adjudication, the CRM 197 It is the most commonly used immunogenic vector in vaccine design for human vaccination programs. For this purpose, the most reactive of the two disulfide bridges in this protein (C186-C201) is selectively reduced in TCEP and rebridged with a linker containing an azide group. The copper-free click reaction between this group and the cyclooctylene moiety mounted at the N-terminus of the antigen allows for the production of a vaccine with a single-copy antigen, as confirmed by LC-MS assays. MD simulations of the conjugate show that CRM 197 The 3D structure remains unchanged after the addition of the antigen, and its determinants are exposed to the solvent, which is crucial for recognition by immune system cells.

[0246] The vaccine was tested in mice and elicited a significant immune response, primarily producing IgG2b antibodies. We also inoculated mice with human colon adenocarcinoma cells and observed reduced tumor size in vaccine-treated mice compared to those exposed to negative controls. Furthermore, we found that the vaccine stimulated T cell production, which plays a crucial role in promoting a potent cytotoxic T lymphocyte (CTL) response, thereby effectively inhibiting tumor growth in mice after inoculation. Notably, the vaccine also demonstrated excellent therapeutic efficacy against this type of cancer, prolonging survival in vaccine-treated mice after tumor inoculation. In mouse models of colon and pancreatic cancer, the vaccine also showed significant delay in tumor growth and improved survival probability. Importantly, its efficacy was further enhanced when combined with a PD-1 immune checkpoint inhibitor, indicating a synergistic potential for improved survival in mouse models. Moreover, the strategy proposed in this work avoids batch-to-batch variations in vaccine production, which is crucial for developing novel, chemically defined, and effective glycopeptide-based cancer vaccines. Finally, although it is generally believed that glycoconjugated vaccines require multiple copies of the antigen to be displayed on a protein vector, our work demonstrates that a single copy of a non-natural, potent antigen precisely displayed on a protein vector can induce a strong immune response in vivo.

[0247] References

[0248] 1. J. Taylor-Papadimitriou, JM Burchell, R. Graham, R. Beatson, Latest developments in MUC1 immunotherapy. Biochem. Soc. Trans. 46, 659-668 (2018).

[0249] 2. V. Apostolopoulos, L. Stojanovska, SE Gargosky, MUC1(CD227): amulti-tasked molecule. Cell. Mol. Life Sci. 72, 4475-4500 (2015).

[0250] 3. DW Kufe, Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874-885 (2009).

[0251] 4. S. Nath, P. Mukherjee, MUC1: a multifaceted oncoprotein with a keyrole in cancer progression. Trends in Mol. Med. 20, 332-342(2014).

[0252] 5. S. S. Pinho, C. A. Reis, Glycosylation in cancer: mechanisms andclinical implications. Nat. Rev. Cancer 15, 540-555(2015).

[0253] 6. A. M. González-Ramírez et al. , Structural basis for the synthesisof the core 1 structure by C1GalT1. Nat. Commun. 13, 2398(2022).

[0254] 7. U. Karsten, Binding patterns of DTR-specific antibodies reveal aglycosylation-conditioned tumor-specific epitope of the epithelial mucin(MUC1). Glycobiology 14, 681-692(2004).

[0255] 8. Y. Yoshimura et al. , Products of Chemoenzymatic SynthesisRepresenting MUC1 Tandem Repeat Unit with T-, ST- or STn-antigen RevealedDistinct Specificities of Anti-MUC1 Antibodies. Sci. Rep. 9(2019).

[0256] 9. T. Ju, V. I. Otto, R. D. Cummings, The Tn antigen-structuralsimplicity and biological complexity. Angew. Chem. Int. Ed. 50, 1770-1791(2011).

[0257] 10. O. Blixt et al. , Autoantibodies to aberrantly glycosylated MUC1in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 13, R25(2011).

[0258] 11. H. Chen, S. Werner, S. Tao, I. Zörnig, H. Brenner, Bloodautoantibodies against tumor-associated antigens as biomarkers in earlydetection of colorectal cancer. Cancer Lett 346, 178-187(2014).

[0259] 12. R. M. Wilson, S. J. Danishefsky, A Vision for Vaccines Built fromFully Synthetic Tumor-Associated Antigens: From the Laboratory to the Clinic. J. Am. Chem. Soc. 135, 14462-14472(2013).

[0260] 13. M. A. Wolfert, G. J. Boons, Adaptive immune activation:glycosylation does matter. Nat. Chem. Biol. 9, 776-784(2013).

[0261] 14. T. Buskas, P. Thompson, G.-J. Boons, Immunotherapy for cancer:synthetic carbohydrate-based vaccines. Chem. Commun. 10.1039 / B908664C, 5335-5349(2009).

[0262] 15. N. Gaidzik, U. Westerlind, H. Kunz, The development of syntheticantitumour vaccines from mucin glycopeptide antigens. Chem. Soc. Rev. 42,4421-4442(2013).

[0263] 16. T. Gao, Q. Cen, H. Lei, A review on development of MUC1-basedcancer vaccine. Biomedicine & Pharmacotherapy 132, 110888(2020).

[0264] 17. N. Stergiou et al. , The Development of Vaccines from SyntheticTumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent ImmuneResponse. Chem. Rec. 21, 3313-3331(2021).

[0265] 18. D. Feng, A. S. Shaikh, F. Wang, Recent Advance in Tumor-associated Carbohydrate Antigens(TACAs)-based Antitumor Vaccines. ACS Chem. Biol. 11, 850-863(2016).

[0266] 19. T. Gao, Q. Cen, H. Lei, A review on development of MUC1-basedcancer vaccine. Biomed. Pharmacother.132, 110888(2020).

[0267] 20. A. Asín et al. , Structure-based Design of Anti-cancer Vaccines:The Significance of Antigen Presentation to Boost the Immune Response. Curr. Med. Chem. 28, 1-13(2021).

[0268] 21. N. Martinez-Saez, J. M. Peregrina, F. Corzana, Principles ofmucin structure: implications for the rational design of cancer vaccinesderived from MUC1-glycopeptides. Chem. Soc. Rev. 46, 7154-7175(2017).

[0269] 22. C. Nativi, F. Papi, S. Roelens, Tn antigen analogues: thesynthetic way to “upgrade” an attracting tumour associated carbohydrateantigen(TACA). Chem. Commun. 55, 7729-7736(2019).

[0270] 23. B. Richichi et al. , A Cancer Therapeutic Vaccine based onClustered Tn-Antigen Mimetics Induces Strong Antibody-Mediated ProtectiveImmunity. Angew. Chem. Int. Ed. 53, 11917-11920(2014).

[0271] 24. I. Companon et al., Structure-Based Design of Potent Tumor-Associated Antigens: Modulation of Peptide Presentation by Single-Atom O / S orO / Se Substitutions at the Glycosidic Linkage. J. Am. Chem. Soc. 141, 4063-4072(2019).

[0272] 25. E. Malito et al. , Structural basis for lack of toxicity of thediphtheria toxin mutant CRM197. Proc. Natl. Acad. Sci. USA 109, 5229-5234(2012).

[0273] 26. H. R. Shinefield, Overview of the development and current use ofCRM197 conjugate vaccines for pediatric use. Vaccine 28, 4335-4339(2010).

[0274] 27. A. Pillot et al. , Site-Specific Conjugation for Fully ControlledGlycoconjugate Vaccine Preparation. Front. Chem. 7(2019).

[0275] 28. A. Amedei et al. , A Structurally Simple Vaccine Candidate ReducesProgression and Dissemination of Triple-Negative Breast Cancer. iScience 23,101250(2020).

[0276] 29. N. Martínez-Sáez et al., Oxetane Grafts Installed Site-Selectively on Native Disulfides to Enhance Protein Stability and Activity InVivo. Angew. Chem. Int. Ed. 56, 14963-14967(2017).

[0277] 30. F. Carboni et al. , Retaining the structural integrity ofdisulfide bonds in diphtheria toxoid carrier protein is crucial for theeffectiveness of glycoconjugate vaccine candidates. Chem. Sci. 13, 2440-2449(2022).

[0278] 31. G. Stefanetti et al. , Sugar–Protein Connectivity Impacts on theImmunogenicity of Site-Selective Salmonella O-Antigen GlycoconjugateVaccines. Angew. Chem. Int. Ed. 54, 13198-13203(2015).

[0279] 32. Q.-Y. Hu, F. Berti, R. Adamo, Towards the next generation ofbiomedicines by site-selective conjugation. Chem. Soc. Rev. 45, 1691-1719(2016).

[0280] 33. K. B. Horwitz, M. B. Mockus, B. A. Lessey, Variant T47D humanbreast cancer cells with high progesterone-receptor levels despite estrogenand antiestrogen resistance. Cell28, 633-642(1982).

[0281] 34. V. M. Kavsan, A. V. Iershov, O. V. Balynska, Immortalized cellsand one oncogene in malignant transformation: old insights on newexplanation. BMC Cell Biol. 12, 23(2011).

[0282] 35. J. Akagi et al. , Therapeutic Antitumor Response AfterImmunization with an Admixture of Recombinant Vaccinia Viruses Expressing aModified MUC1 Gene and the Murine T-Cell Costimulatory Molecule B7. J. Immunother. 20, 38-39(1997).

[0283] 36. Case DA, Belfon K, Ben-Shalom IY, Brozell SR, DSCerutti, Cheatham TE, VWD Cruzeiro, Darden TA, Duke RE, Giambasu G, Gilson MK, Gohlke H, Goetz AW, Harris R, Izadi S, Iz-mailov SA, Kasavajhala K, Kovalenko A, Krasny R, Kurtzman T, Lee TS, LeGrand S, Li, C, Liu, J, Luchko, R, Luo, V, Man, KM, Merz, Y, Miao, O, Mikhailovskii, G, Monard, H, Nguyen, A, Onufriev, F, Pan, S, Pantano, R, Qi, DR, Roe, A, Roitberg, Sagui C, Schott-Verdugo S, Shen J, Simmerling CL, Skrynnikov NR, Smith J, Swails J, Walker RC, Wang J,L. Wilson , RM Wolf , X. Wu , Y. Xiong , Y. Xue , DM York and PA Kollman ( 2020 ), AMBER 2020 , University of California, San Francisco.

[0284] 37. JA Maier et al. , ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J. Chem. Theory Comput. Rev. 11.3696–3713(2015).

[0285] 38. J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, D. A. Case, Development and testing of a general amber force field. J. Comput. Chem. 25,1157-1174(2004).

[0286] 39. W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey, M. L. Klein, Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935(1983).

[0287] 40. H. C. Andersen, Molecular dynamics simulations at constant pressure and / or temperature. J. Chem. Phys. 72, 2384-2393(1980).

[0288] 41. S. Miyamoto, P. A. Kollman, Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comp. Chem. 13, 952-962(1992).

[0289] 42. T. Darden, D. York, L. Pedersen, Particle mesh Ewald: An N log(N) method for Ewald sums in large systems. J. of Chem. Phys. 98, 10089-10092(1993).

[0290] Sequence

[0291] AX1DX2RP

[0292] where X1 is 4 S -4-fluoro-L-proline and X2 isS -(α-D-GalNAc)-threonine thioether

[0293] SEQ ID NO: 1

[0294] HGVTSAX1DX2RPAPGSTAPPA

[0295] where X1 is 4 S -4-fluoro-L-proline and X2 is S -(α-D-GalNAc)-threonine thioether

[0296] SEQ ID NO: 2.

[0297] GADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKEFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTQPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIKITAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVAFHRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVNSKLSLFFEIKS

[0298] SEQ ID NO: 3 – CRM 197 Amino acid sequence

Claims

1. A cancer vaccine conjugate, its salt, solvate, and protected form, said cancer vaccine conjugate comprising: CRM 197 Carrier proteins, Immunogenic peptides, and Linker that connects the immunogenic peptide to the CRM 197 The vector residues C186 and C201 are covalently linked.

2. The cancer vaccine conjugate of claim 1, wherein the cancer vaccine conjugate stimulates an immune response against cancer cells.

3. The cancer vaccine conjugate according to claim 1 or claim 2, wherein the immunogenic peptide comprises a tumor-associated antigen (TAA).

4. The cancer vaccine conjugate according to any one of claims 1 to 3, wherein the immunogenic peptide is a glycopeptide.

5. The cancer vaccine conjugate according to any one of claims 1 to 4, wherein the immunogenic glycopeptide comprises tumor-associated carbohydrate antigen (TACA).

6. The cancer vaccine conjugate according to any one of claims 1 to 5, wherein the tumor-associated carbohydrate antigen (TACA) is GalNAc, Galb(1,3)GalNAc or Neu5Acα(2-6)GalNAc.

7. The cancer vaccine conjugate according to any one of claims 1 to 6, wherein the tumor-associated carbohydrate antigen (TACA) is linked to the immunogenic glycopeptide via a glycosidic bond.

8. The cancer vaccine conjugate according to any one of claims 1 to 7, wherein the glycosidic bond is an O-glycosidic bond, an S-glycosidic bond, or a Se-glycosidic bond.

9. The cancer vaccine conjugate according to any one of claims 1 to 8, wherein the immunogenic glycopeptide comprises two or more TACAs.

10. The cancer vaccine conjugate according to any one of claims 1 to 9, wherein the two or more TACAs are the same or different.

11. The cancer vaccine conjugate according to any one of claims 1 to 10, wherein the immunogenic glycopeptide is a natural or synthetic MUC1 glycopeptide.

12. The cancer vaccine conjugate of claim 11, wherein the immunogenic glycopeptide comprises the amino acid sequence AX1DX2RP (SEQ ID NO: 1) or a variant thereof, wherein X1 is 4. S -4-Fluoro-L-proline, and X2 is S -(α-D-GalNAc)-thiothreonine.

13. The cancer vaccine conjugate of claim 12, wherein the immunogenic glycopeptide comprises the amino acid sequence HGVTSAX1DX2RPAPGSTAPPA (SEQ ID NO: 2) or a variant thereof, wherein X1 is 4. S -4-Fluoro-L-proline, and X2 is S -(α-D-GalNAc)-thiothreonine.

14. The cancer vaccine conjugate according to any one of the preceding claims, wherein the CRM 197 The carrier protein contains the amino acid sequence of SEQ ID NO: 3 or a variant thereof.

15. The cancer vaccine conjugate according to any one of the preceding claims, wherein the linker comprises a component selected from C1-C1. 20 One or more groups including alkylene groups, (poly)ethylene glycol moieties, alkylene diamine moieties, amino acid residues, and combinations thereof.

16. The cancer vaccine conjugate according to any one of the preceding claims, wherein the linker is a group of the following formula: in; n is an integer selected from 1 to 4; m is an integer selected from 2 to 8; The CRM mentioned 197 The carrier protein residues C186 and C201, the linker and the CRM 197 The carrier protein is linked at the two residues mentioned above; and Indicates the location where the linker is connected to the immunogenic glycopeptide.

17. A method for preparing cancer vaccine conjugates, comprising: CRM provided with covalent connection to the first connector 197 Carrier proteins, The first connector is connected to the CRM 197 The carrier protein has residues C186 and C201 covalently linked and contains a first reactive group. Provides an immunogenic glycopeptide covalently linked to a second linker. The second linker contains a second reactive group. The first reactive group and the second reactive group react to covalently link the first linker and the second linker, thereby linking the immunogenic glycopeptide to the CRM. 197 The cancer vaccine conjugate is generated on the carrier protein.

18. The method of claim 17, wherein the first reactive group and the second reactive group are selected from the following pairings: i) Azides and alkynes; ii) Ketones or aldehydes and alkoxyamines (e.g., hydroxylamine) or hydrazine; iii) Amine groups and acyl halides or carboxylic acids; iv) Electron-rich dienes (e.g., 1,3-nitroketenes) and electron-deficient dienes (e.g., tetrazines); and v) Strained alkenes or alkynes (e.g., norbornene or cyclooctyne) and tetrazines.

19. The method according to claim 17 or claim 18, wherein one of the first reactive group and the second reactive group is an azide (azide group), and the other of the first reactive group and the second reactive group is an alkyne (alkynyl group).

20. The method according to any one of claims 17 to 19, wherein the CRM 197 The first linker covalently linked to the carrier protein is a group of the following formula: in: n is an integer from 1 to 4, preferably 2; and The CRM mentioned 197 The carrier protein residues C186 and C201, the linker and the CRM 197 The carrier protein is linked at the two residues mentioned above.

21. The method according to any one of claims 17 to 20, wherein the second linker covalently linked to the immunogenic glycopeptide is a group of the following formula: in: m is an integer from 2 to 8, preferably 4; and Indicates the location where the linker is linked to the immunogenic glycopeptide (e.g., MUC-1 glycopeptide).

22. The method according to any one of claims 17 to 21, wherein the CRM 197 The carrier protein is covalently linked to the first linker by the following method, the method comprising: Provide CRM 197 Carrier proteins, Selectively restore the CRM 197 The C186-C201 disulfide bond of the carrier protein, in the CRM 197 Free thiol groups are generated at residues C186 and C201 of the carrier protein. A first linker compound is provided, comprising a first reactive group, a third reactive group, and a fourth reactive group, and The third and fourth reactive groups of the first linker compound are reacted with the free thiol groups at C186 and C201, respectively, so that the first linker reacts with the CRM. 197 The carrier protein residues C186 and C201 are covalently linked, thereby enabling the CRM to... 197 The carrier protein is covalently linked to the first linker.

23. The method according to claim 22, wherein the third reactive group and the fourth reactive group are halide groups, such as chloride groups.

24. The method according to claim 22 or claim 23, wherein the first linker compound is a compound of the following formula: Where n is an integer selected from 1 to 4 (e.g., 2).

25. A kit for producing cancer vaccine conjugates, comprising: CRM 197 A carrier protein, covalently linked to a first linker, wherein the first linker is connected to CRM 197 The carrier protein has residues C186 and C201 covalently linked and contains a first reactive group.

26. The kit of claim 25, wherein the CRM 197 The carrier protein is as defined in claim 14, and the first linker is as defined in claim 20.

27. A pharmaceutical composition comprising the cancer vaccine conjugate of any one of claims 1 to 16 and a pharmaceutically acceptable excipient.

28. The pharmaceutical composition according to claim 27, further comprising an adjuvant.

29. A treatment for cancer, comprising administering to an individual in need a cancer vaccine conjugate according to any one of claims 1 to 16 or a pharmaceutical composition according to any one of claims 27 to 28.

30. The cancer vaccine conjugate according to any one of claims 1 to 16 or the pharmaceutical composition according to any one of claims 27 to 28, for the treatment of cancer.

31. Use of the cancer vaccine conjugate according to any one of claims 1 to 16 or the pharmaceutical composition according to any one of claims 27 to 28 in the manufacture of a medicament for treating cancer.

32. The method of claim 29, the cancer vaccine conjugate or pharmaceutical composition of claim 30, or the use of claim 31, wherein the immunogenic peptide is a natural or synthetic MUC1 glycopeptide, and the cancer is characterized by overexpression of mucin-1 or expression of aberrantly glycosylated mucin-1.

33. The method of claim 29 or 32, the cancer vaccine conjugate or pharmaceutical composition of claim 30 or 32, or the use of claim 31 or 32, wherein the cancer vaccine conjugate is administered in combination with an immune checkpoint inhibitor.

34. The method of claim 33, the cancer vaccine conjugate or pharmaceutical composition of claim 33, or the use of claim 33, wherein the immune checkpoint inhibitor is a PD-1 immune checkpoint inhibitor.

35. The method of claim 34, the cancer vaccine conjugate or pharmaceutical composition of claim 34, or the use of claim 34, wherein the PD-1 immune checkpoint inhibitor is an anti-PD-1 antibody.

36. The method of claim 29 or 32 to 35, the cancer vaccine conjugate or pharmaceutical composition of claim 30 or 32 to 35, or the use of claim 31 to 35, wherein the cancer vaccine conjugate is administered for a therapeutic treatment of cancer in the individual.

37. The method of claim 29 or 32 to 35, the cancer vaccine conjugate or pharmaceutical composition of claim 30 or 32 to 35, or the use of claim 31 to 35, wherein the cancer vaccine conjugate is administered for the preventive treatment of cancer in the individual.

Citation Information

Patent Citations

  • Data recording method and system, and access server

    WO2015123986A1

  • Oxadiazole linkers and use thereof

    WO2019011078A1